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Valvular heart disease (VHD) is a major source of morbidity and mortality leading to 
approximately 290,000 valve replacement surgeries worldwide each year. Current replacement 
prosthetics include mechanical and bioprosthetic heart valves, which are burdened by chronic 
anticoagulation therapy and tissue degeneration, respectively, as well as an inability to grow and 
remodel. Tissue engineered heart valves (TEHVs) have been proposed to overcome these 
limitations by providing a scaffold that is designed to be gradually replaced by autologous 
functional tissue. As such, TEHVs should degrade at a rate matching new tissue formation to 
achieve proper function and avoid structural failure. 
Biodegradable polyurethane elastomers are suitable candidates for TEHVs and offer 
tunable degradability based on soft segment chemistry. Polyester soft segments in poly(ester 
urethane)urea (PEUU) generate faster degradation than polycarbonate soft segments in 
poly(carbonate urethane)urea (PCUU). These biodegradable polyurethanes can be electrospun 
into fully assembled, fibrous TEHVs. The objectives of this study were to evaluate the in vitro 
degradation profile of three polyurethane soft segment mixing strategies and the effects of a 
mechanically demanding environment on the degradation rate. Equal ratios of faster-degrading 
polyester and slower-degrading polycarbonate segments were mixed into polyurethanes using 
three strategies: 1) soft segment mixing during synthesis to form poly(ester carbonate 
urethane)urea, 2) physical blending of PEUU and PCUU polymers during solvation to form a 
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 v 
single solution, and 3) electrospinning from two independent streams of PEUU and PCUU 
solutions. These mixing strategies varied the chemical composition of the polymer chains and 
electrospun fibers between groups. 
Electrospun TEHVs from each mixing strategy were subjected to accelerated degradation 
in a pulse duplicator with enzymatic solution for two weeks. Relative degradation rates were 
quantified based on scaffold mass and thickness loss, macro- and microscopic structural changes, 
and viscosity reduction. Additionally, biaxial mechanical compliance was monitored throughout 
degradation and initial scaffold blood compatibility was assessed. Soft segment mixed TEHVs 
had the most degradation while co-spun TEHVs degraded very little. Additionally, mechanical 
strength was maintained for each mixing strategy throughout degradation. Findings of this study 
are instrumental in efficiently designing TEHVs where tunable degradation is critical to match 
the in vivo tissue formation rate. 
 vi 
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 1 
1.0  INTRODUCTION 
1.1 PROSTHETIC HEART VALVES 
1.1.1 Epidemiology and etiology of heart valve disease 
Cardiovascular disease is the leading cause of death in the United States [1] and includes 
diseases that affect either the heart or blood vessels. Diseases involving the heart include 
cardiomyopathy, heart failure, cardiac dysrhythmias, and valvular heart disease. Valvular heart 
disease (VHD) is a major source of morbidity and mortality in the United States and around the 
world [2]. While VHD affects 2.5% of the United States population [2], there are approximately 
90,000 valve replacement surgeries in the United States [3] and 290,000 worldwide each year 
[4], and this number is expected to increase with the aging population. Additionally, valvular 
defects are present in 1% of newborns [5]. The market for heart valve repair and replacement is 
estimated at $2.8 billion with an anticipated growth rate of 9.1% annually [6]. 
VHD is classified as dysfunction in any of the four heart valves: aortic, mitral, 
pulmonary, and tricuspid, which typically arises from either valvular stenosis or regurgitation. 
Valvular stenosis is the inability of the valve to fully open, resulting in a narrow opening for 
blood flow, often caused by stiffening of the leaflets. Alternatively, valvular regurgitation, or 
insufficiency, is characterized by the inability of the valve to close completely and results in the 
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backflow of blood [7]. Both scenarios force the heart to work harder to either pump enough 
blood through a small opening or sufficiently overcoming a backflow of blood. The high 
pressures on the left side of the heart make those valves more susceptible, and consequently, 
aortic and mitral valve stenosis and regurgitation are the most common forms of VHD [8]. 
Rheumatic heart disease is the major cause of VHD in developing countries. 
Industrialized countries, which have had a major reduction in rheumatic disease, still have a large 
occurrence of VHD typically caused by degenerative processes [2, 9]. Other mechanisms such as 
endocarditis, inflammatory processes, congenital malformations, and ischemia can also 
contribute [8]. Although valve repair is the preferred surgical treatment for patients with VHD, 
some valves cannot be repaired and require replacement surgery [10], typically with a prosthetic 
heart valve. 
1.1.2 Current heart valve technology: mechanical and bioprosthetic 
Current technologies for heart valve replacement surgeries include two categories of prosthetic 
heart valves: mechanical and bioprosthetic. Mechanical heart valves are produced from synthetic 
materials such as polymer and metal (e.g. stainless steel, titanium). Traditionally, bileaflet, 
monoleaflet, and ball-in-cage are the three common mechanical prosthetic valve designs [3], 
shown in Figure 1. The bileaflet valve, produced by St. Jude Medical, is the most common 
mechanical prosthesis and operates by the opening and closing of semicircular leaflets that form 
three orifices. The monoleaflet, or single-tilting-disk valve, manufactured by Medtronic-Hall, 
functions by a single disk tilting between two struts to create two orifices. The ball-in-cage 
valve, manufactured by Starr-Edwards, operates by a ball moving forward or backward in a cage 
as the valve opens and closes [11]. 
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Figure 1. Mechanical heart valves. A) Bileaflet, B) monoleaflet, and C) ball-in-cage (from [3]). 
 
Alternatively, bioprosthetic heart valves are constructed using homogeneic (autologous or 
allogeneic) or xenogeneic tissue sources. An autologous valve is used in the Ross procedure 
when a patient has the pulmonary valve removed and repositioned in the aortic root [7]. For 
humans, allogeneic heart valves from cadavers have many desirable properties. However, 
xenogeneic tissue valves, harvested from porcine or bovine, are by far the most common and are 
typically in the form of porcine aortic valves or bovine pericardium [12]. Bioprosthetic heart 
valves are usually fixed in glutaraldehyde to cross-link the collagen and lyse the cells to decrease 
the chance of an immune reaction [12].   
Medtronic (Minneapolis, MN), St. Jude Medical (St. Paul, MN), and Edwards 
Lifesciences (Irvine, CA) are the three major bioprosthetic valve manufactures that produce 
several types of bioprosthetic valves. For example, the Medtronic Mosaic, Medtronic Hancock 
II, St. Jude Medical Epic, and Edwards Lifesciences Carpentier-Edwards porcine are stent valves 
from porcine leaflets. Bovine pericardium is used with the St. Jude Medical Trifecta and 
Edwards Lifesciences Carpentier-Edwards Perimount to form a stented valve. As a stentless 
approach, the Medtronic Freestyle, St. Jude Medical Toronto SPV, and Edwards Lifesciences 
Prima use porcine root leaflets [13]. Figure 2 shows an example of the bioprosthetic valves 
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listed above. Another manufacturer, Sorin (Milan, Italy) produces the Mitroflow and Soprano 
Armonia valves, both of which are stented bovine pericardium [13]. 
 
 
Figure 2. Bioprosthetic heart valves. Examples of porcine and bovine stented and stentless bioprosthetic valves 
from A-C) Medtronic, D-F) St. Jude Medical, and G-I) Edwards Lifesciences (from [13]). 
 
1.1.3 Limitations of prosthetic heart valves 
Prosthetic heart valves are burdened with a number of issues related to the long-term use of the 
device. One major problem that exists in both types of prostheses is the inability to grow and 
adapt with the patient. This is particularly problematic for the pediatric population as prostheses 
can reduce pediatric life expectancy by 50% while subjecting them to lifetime valve morbidity 
[14]. Because these valves cannot grow with the patient, a child receiving a prosthetic valve will 
 5 
undergo replacement surgery every few years to increase the size until he or she is fully grown 
[15]. 
Mechanical prostheses require chronic anticoagulation therapy, such as warfarin, to 
control thromboembolism from blood contact with the synthetic surface [3]. Consequently, 
hemorrhages can form as a result of the therapy, and this puts the patient at an increased risk for 
excessive bleeding [16]. This prosthesis is particularly difficult for younger patients as it limits 
their activity. Prosthetic endocarditis is also possible with these valves as bacteria enters the 
blood stream through incomplete sterilization of the prostheses or other points of entry in the 
body [4]. In addition, the various geometries and different orifices cause suboptimal 
hemodynamic performance, which can lead to stagnant blood or poor perfusion [4, 17]. 
Bioprosthetic heart valves are limited in their durability as the biological tissue leaflets 
typically begin to degenerate after 7-8 years [3, 12] and will completely degenerate in 10-20 
years [7]. The rate of degeneration is higher in younger patients, particularly those under the age 
of 40, due to higher stresses and pressures on the prosthesis [3]. Degeneration is characterized by 
tearing, thickening, or stiffening of the leaflets, and there are several mechanisms for 
bioprosthetic degeneration including infective endocarditis, calcification, thrombosis, pannus 
formation, and pressure. 
Infective endocarditis of the bioprostheses can result from bacteria entering the 
bloodstream or a previous case of endocarditis, where the tissue leaflet supports the growth of 
bacteria, which can lead to tearing or stenosis [12, 17]. Glutaraldehyde fixation of the 
xenogeneic tissue releases calcium from lysed cells in the tissue causing calcium nucleation as 
well as other components to react with circulating calcium ions, all of which reacts with 
phospholipids to cause calcification of the prosthesis. This can lead to either regurgitation from 
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leaflet tears or stenosis associated with leaflet stiffening [12, 17]. Thrombus formation, although 
infrequent in bioprostheses, can occur from a lack of short-term anticoagulation therapy or 
asymmetrical valves resulting in static blood [12, 17]. Pannus formation can lead to leaflet 
stiffening and displaced stress loads when cells at the site of the injury (e.g. myofibroblasts, 
fibroblasts) overextend onto the leaflets. Although some pannus formation can assist in healing 
and reduce thrombogenicity, it can also cause stenosis, regurgitation, and calcification [12, 17]. 
High pressures within the heart can also lead to degeneration, particularly at the commissures, 
where there is a high stress concentration [12, 17]. 
The specific drawbacks of each of these prostheses have led to the development of 
criteria for identifying the best option for the patient. Age and life expectancy are major factors 
in determining the prosthesis, and it is typically recommended that patients under the age of 65 
and with a longer life expectancy receive a mechanical prosthesis. However, a woman of child 
bearing age that may become pregnant is advised for a bioprosthetic valve. Additionally, those 
already on warfarin therapy would be advised for a mechanical valve while others with a contra-
indication for warfarin would be directed toward a bioprosthetic valve [3]. 
1.2 TISSUE ENGINEERED HEART VALVES 
Tissue engineered heart valves (TEHVs) have been proposed as a solution to overcome the 
existing limitations of mechanical and bioprosthetic heart valves. These valves are targeted 
toward a younger patient population with engineering focused on tissue remodeling and growth 
over time. Specifically, engineered valves are being designed to mimic the native physiological 
functions of a heart valve with proper hemodynamic performance, support new tissue growth and 
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corresponding scaffold degradation, reduce thrombogenicity and calcification, and/or be 
delivered percutaneously with a catheter. Research is being conducted on numerous tissue 
designs involving decellularized tissues, synthetic polymers, or biologic materials for structurally 
robust tissue combined with a cell source, growth factors, and/or other synthetic materials to 
promote growth and remodeling [4, 18]. There have been numerous strategies for developing 
TEHVs over the past 20 years, and the two main approaches to engineering these constructs are 
in vitro or in situ tissue growth [19]. 
1.2.1 Review of tissue engineered heart valves  
The in vitro approach to TEHVs generates a construct with new tissue prior to implantation by 
seeding cells onto a scaffold and then incubating or conditioning them in a bioreactor. With this 
method, various autologous cell sources have been identified and harvested, expanded in cell 
culture, and then seeded onto the scaffold matrix. Bioreactors with pulsatile flow are often used 
to simulate the pressures and mechanical conditions experienced by the valves in the body. For 
example, Flanagan et al. [20] seeded fibrin heart valves with ovine carotid artery cells and 
conditioned the construct on a bioreactor to increase cell attachment and extracellular matrix 
(ECM) production. The drawbacks of this approach are lengthy production times for one scaffold 
and the complexity of the process which increases regulatory difficulty [19]. 
The alternative TEHV approach is in situ engineering where heart valve scaffolds are not 
incubated or conditioned prior to implantation. This simpler approach involves implanting 
scaffold matrices, which may or may not be seeded with cells, directly into the heart of a 
recipient and using the body as a bioreactor to populate the scaffold and regenerate tissue. An 
example is the synthetic scaffold with a nitinol stent in Emmert et al. [21] which was seeded with 
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autologous bone marrow mononuclear cells and implanted immediately. These scaffolds benefit 
from decreased manipulation prior to implantation and a quicker production process with less 
stringent regulatory approvals. The main disadvantage with this approach is that the recipient 
must have the ability to regenerate tissue [19]. 
Scaffold materials for these approaches are typically derived from two sources: 
decellularized heart valves or artificial materials. Decellularization of valves prevents an immune 
response in the recipient by removing all cells, but maintains the components of the ECM that 
provide structural support. Decellularized heart valves can be either allogenic [22, 23], such as a 
decellularized pulmonary valve from the same species, or xenogeneic [24-27], like decellularized 
pulmonary valves from a different species. Artificial materials range from synthetic to natural 
polymers and can be either fibrous, porous, or a hydrogel [28], each having specific benefits. 
Porous scaffolds serve to create a network of pores for nutrients and waste to flow thorough in 
order to support tissue growth and vascularization [28], and can be formed with methods such as 
thermally induced phase separation, particulate leaching, and solvent casting. Meanwhile, fibrous 
scaffolds, which can be produced by electrospinning, are assembled to resemble ECM structure 
to promote cell adhesion to the surface, migration along the scaffold, and differentiation into 
specific cell types. 
Dohmen et al. [22, 23] employed an allogeneic approach by decellularizing pulmonary 
valves from other humans. These decellularized valves were repopulated with autologous 
vascular endothelial cells from the human recipient before implantation. Using a xenogeneic 
method, Metzner et al. [25] developed a decellularized porcine pulmonary valve with an 
expandable nitinol stent. Endothelial cells and myofibroblasts from the recipient sheep were 
loaded onto the decellularized tissue and delivered percutaneously. This xenogeneic approach 
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was applied to humans by Perri et al. [26] who replaced pulmonary valves in patients with 
decellularized porcine pulmonary valves without the addition of cells before implantation. 
Similarly, Simon et al. [27] studied Synergraft™, a decellularized porcine heart valve without a 
cell source, in pediatric patients. Decellularized porcine pericardium was used by Tedder et al. 
[24], and penta-galloyl glucose, as opposed to glutaraldehyde, was used to stabilize collagen. 
These scaffolds were seeded with rat aortic fibroblasts before implanting them into a rat model. 
Rotary jet spinning was used by Badrossamay et al. [29] to create constructs from blends 
of polycaprolactone (PLC) and gelatin or collagen before seeding them with several cell types. 
Capulli et al. [30] modified these scaffolds to contain poly-4-hydroxybutyrate (P4HB) and 
gelatin. Addition of a nitinol stent provided the ability for a minimally invasive delivery in an 
ovine model. Molding was used by Syedain et al. [31] to create a fibrin gel seeded with neonatal 
human dermal fibroblasts, and the scaffold was cultured for 5 weeks before implanting in the 
pulmonary position in an ovine model. Syedain et al. [32] then moved to the aortic position with 
a tube matrix consisting mostly of collagen. Ovine and human dermal fibroblasts were 
temporarily used to produce the matrix and were eventually removed from the scaffold as a stent 
was added. In comparison, Reimer et al. [33] used ovine fibroblasts in a mold to produce a 
tubular, stentless collagen matrix which was ultimately decellularized. Molded hyaluronan 
hydrogels were produced by Puperi et al. [34] and seeded with porcine aortic valve interstitial 
cells. 
Early studies by Shinoka et al. [35, 36] used woven polyglactin and polyglycolic acid 
(PGA) as a single leaflet scaffold seeded with ovine endothelial cells and fibroblasts. Other early 
studies using synthetic scaffolds involve the work by Zund et al. [37], which produced  
biodegradable PGA and poly(lactic-co-glycolic acid) (PLGA) scaffolds with in vitro seeding of 
 10 
sheep myofibroblasts and endothelial cells, and Sodian et al. [38], which involved seeding 
autologous arterial valvular cells onto molded polyhydroxyalkanoate (PHA) scaffolds. A PGA 
valve with a P4HB coating and seeded with human marrow stromal cells was developed by 
Hoerstrup et al. [39, 40]. This work was expanded upon by Mol et al. [41] as the design was 
modified with cells from the human vena saphena magna and a Fastacryl stent, and then Emmert 
et al. [42] altered the design with a nitinol stent and autologous bone marrow mononuclear cells 
for in vivo studies which could be delivered with a transcatheter delivery system. Recently, 
Moreira et al. [43] developed a knit polyethylene terephthalate (PET) tubular mesh and seeded it 
with ovine smooth muscle cells and fibroblasts. Kidane et al. [44] demonstrated the possibility of 
using polyhedral oligomeric silsesquioxanes with polycarbonate soft segments for engineered 
valves. 
Other popular heart valve production methods include 3D printing and electrospinning. 
Hockaday et al. [45] 3D printed an aortic valve and root from poly(ethylene glycol) (PEG) 
diacrylate and seeded it with porcine aortic valve interstitial cells. Methacrylated hyaluronic acid 
and methacrylated gelatin were 3D printed to encapsulate human aortic valve interstitial cells by 
Duan et al. [46]. Electrospun heart valves were introduced by van Lieshout et al. [47] as multiple 
layers of PCL were electrospun onto a mold and then seeded with human myofibroblasts. 
Similarly, Del Gaudio et al. [48] electrospun PCL into a trileaflet valve without a stent. Recently, 
Tseng et al. [49] modified electrospun PCL and embedded it within a PEG hydrogel before 
seeding with valvular interstitial cells. An acellular approach by Kluin et al. [50] electrospun 
polycarbonate on a supporting polyether ether ketone stent which was implanted in an ovine 
model for up to 12 months. Finally, D’Amore et al. [51] electrospun fully assembled 
biodegradable valves using  a mandrel with heart valve anatomical geometry. 
 11 
With the acellular in situ approaches, scaffolds must be populated with endogenous cells 
from the surrounding tissue and circulating blood. This can be achieved with both biological 
scaffolds, as Tudorache et al. [52] demonstrated with the repopulation of decellularized 
pulmonary allografts, and synthetic scaffolds, demonstrated by Kluin et al. [50] with electrospun 
bis-urea modified polycarbonate into a pulmonary valve. Use of an acellular, synthetic heart 
valve with the in situ approach allows for control over a number of other valve properties (e.g. 
mechanics, size, geometry), does not require complex and time consuming processing, and 
donors are not needed for the scaffold material. A visual representation of these TEHV devices 
are included in Figure 3.  
 
 
Figure 3. Tissue engineered heart valves. Valves from decellularized xenografts A) from [25]; natural materials B) 
from [33], C) from [20], D) from [31]; combinations of natural and synthetic materials E) from [30]; synthetic 
materials F) from [40], G) from [39], H) from [41], I) from [42], J) from [44]; 3D printing K) from [45], L) from 
[46]; and electrospinning M) from [48], N) from [50], O) from [51]. 
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1.2.2 Mechanical properties of tissue engineered heart valves 
Heart valves function in a mechanically demanding environment with cyclic loading throughout 
their lifetime. Valves are subjected to complex forces and stresses, rapid blood velocity, and high 
pressures that are constantly changing [15]. TEHVs must be able to function immediately upon 
implantation and support these complex loads without failure. Therefore, mechanical properties 
of TEHVs are important for temporarily supporting the mechanical load and directing new tissue 
development as remodeling occurs. When a valve construct is implanted to augment or replace 
the native tissue, the construct should be load bearing until new tissue begins forming and then 
gradually transfers the stress to the new tissue. Although the construct needs sufficient strength 
to prevent mechanical failure, mechanical mismatch in scaffolds which are too stiff will limit 
movement and cause discomfort. Additionally, the scaffolds should have appropriate mechanics 
to direct cell growth, movement, and differentiation. Mechanical signals can direct ECM 
remodeling at the site of the scaffold [53], and as appropriate de novo collagen synthesis occurs, 
the mechanical load can be transferred from the scaffold. Characterizing the native tissue 
mechanics and then recapitulating those properties in engineered constructs is essential when 
designing TEHVs. 
Mechanical properties which are critical to and often employed in the design of TEHVs 
are uniaxial mechanics, biaxial mechanics, flexural mechanics, and mechanical fatigue [15, 54]. 
Simple material properties like Young’s modulus or ultimate tensile strength of heart valve 
tissues can be evaluated with uniaxial mechanical testing. The stress-stretch curve for these 
native tissues display a non-linear response due to the stretching of crimped collagen fibers in the 
leaflets [15]. Stradins et al. [55] characterized the modulus of elasticity for human aortic and 
pulmonary valves at different anatomical locations on the leaflets. While testing human aortic 
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valve leaflets, Balguid et al. [56] reported differences in tensile properties in the radial and 
circumferential directions of the leaflet. Although uniaxial properties are often evaluated in 
TEHV constructs and are important in understanding strength and failure properties in one 
direction of a tissue, the dynamic motion and complex performance requirements necessitate an 
understanding of the in-plane and out-of-plane mechanics. 
Merryman et al. [54] argues the importance of biaxial and flexural mechanics as they 
relate to heart valve mechanics. Biaxial mechanics of the heart valve leaflet is used to evaluate 
the simultaneous bidirectional (radial and circumferential) in-plane mechanics. The planar 
mechanics are important for the valve when it is coapting and preventing regurgitation. Christie 
and Barratt-Boyes biaxially tested porcine aortic and pulmonary valves [57] and the aortic valve 
from human hearts [58] and found the radial direction of the leaflets to be more compliant than 
the circumferential direction. Recently, the anisotropy ratio of the biaxial mechanics of porcine 
tricuspid valve leaflets was matched in a heart valve scaffold produced by electrospinning with a 
rotating, valve-shaped mandrel [51]. 
Flexural mechanics is another important property as it involves the bending of the valve 
leaflets. These out-of-plane mechanics are important as the valve must open and close 60-100 
times per minutes without failing. The flexure test evaluates the stiffness of the leaflets, and 
depending on which direction the valve is bent, with or against curvature, the leaflet should be 
less stiff and more stiff, respectively [54]. Three-point bending [59] or cantilever bending [60] 
are two methods to understand flexural properties. A complete characterization by Brazile et al. 
[61] presented the flexural rigidity of porcine heart valves at all four valve positions, with- and 
against-curvature. Electrospinning with a low translation speed created a scaffold with similar 
flexural mechanics to a native porcine tricuspid valve [51]. 
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Heart valves are subjected to cyclical loading and unloading with dynamic motion for the 
lifespan of a person, so fatigue testing is critical to evaluate construct durability. Fatigue testing 
can identity stress concentrations or weak point in a heart valve scaffold prior to implantation 
[5]. In one year, the heart will beat over 30 million times and valves will experience continuous 
stresses from leaflet stretching, flexing, or shearing [15]. Gloeckner et al. [62] studied changes in 
leaflet flexural mechanics after fatiguing porcine aortic valves with accelerated durability testing 
and found that the bending stiffness decreased over time. 
Understanding the effects that fatigue has on the aforementioned mechanical properties 
of the heart valves, especially valves on the left side of the heart under greater pressures, is 
critical when designing TEHVs. Although engineered heart valves are not intended to experience 
years of fatigue (e.g. they degrade as new tissue forms), they must maintain their mechanical 
properties before new tissue forms. This emphasizes the importance of understanding mechanical 
degradation, as well as other forms of degradation [63], in biodegradable tissues which could 
accelerate the fatiguing process. Consequently, early losses of scaffold tissue at the site could 
lead to a loss in mechanical strength and eventually tissue mechanical failure [64]. 
1.3 ELECTROSPUN POLYMER PROCESSING 
Electrospinning is a polymer processing technique used to generate fibrous scaffolds for various 
applications. The main feature of this processing method is the ability to produce fibers on a 
submicron scale, which is physiologically relevant for biological scaffolds. Additionally, the 
adaptability of electrospinning allows it to be used in a wide range of applications, including 
 15 
drug delivery and tissue engineering. The ease of use and specific control over scaffold geometry 
make electrospinning an appealing technique for TEHVs. 
1.3.1 Fundamentals of electrospinning 
The basic electrospinning setup, shown in Figure 4, involves a high voltage power source, a 
metal capillary connected to a polymer solution, and a collecting surface [65]. The polymer 
solution, often loaded in a syringe, is forced through the metal capillary by a syringe pump or 
gravity at a certain rate. During this time, an electrode from the high voltage source is connect to 
the capillary and provides the polymer solution with a charge of one polarity. As it is forced out 
of the capillary, the charged polymer solution travels through the air and deposits on the 
collecting surface of opposite polarity as solid fibers. Voltage difference, type and concentration 
of polymer, and shape of the collecting surface are all variables which can be easily modified by 
the user to generate numerous scaffold specifications [65].  
 
 
Figure 4. Schematic of a general electrospinning setup with a single polymer stream (from [65]). 
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The theory behind the polymer solution exiting the capillary tube and accumulating on 
the collecting surface is based on electrostatic force. As the polymer solution is being forced 
through the capillary tube, prior to the initiation of the high voltage power source, a pendant drop 
forms from the end of the capillary tube. Once the power sources are turns on, an electric field is 
created between the capillary tube and the collecting surface. As described in Sill and von 
Recum [65], repulsive forces form within the charged polymer solution while attractive forces 
are created between the polymer solution and collecting surface. Consequently, tensile forces 
begin to stretch the drop of polymer solution. However, these electrostatic forces are competing 
against the surface tension of the solution causing a Taylor cone to form at the tip of the capillary 
when these two forces are equal [65]. If the electric field is then increased further, a jet will erupt 
from the cone and be directed toward the collecting surface of opposite polarity. During this 
time, the jet undergoes bending instability due to the similar charges in the solution. The solvent 
evaporates as the jet moves toward the collector, eventually depositing polymer fibers on the 
collecting surface [65]. 
1.3.2 Desirable characteristics of electrospun scaffolds 
Fibers produced during electrospinning are typically submicron, although they are often referred 
to as nanofibers, and range from 100 to 500 nm [65]. Production of fibrous scaffolds which are 
physiologically relevant is important for directing cell migration and differentiation [66]. 
Orientation of the fibers in a scaffold is relevant as highly aligned fibers produce mechanical 
anisotropy while isotropic mechanical properties result from a random fiber orientation [67]. 
Additionally, an increase in fiber intersections decreases the flexural mechanical stiffness of a 
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scaffold [68]. Although electrospun scaffolds are not highly porous, porosity and pore size can 
be moderately controlled for cell infiltration into the scaffold [65]. 
The electrospinning process has a variety of parameters within the control of the user to 
manipulate the electric field and alter the properties mentioned above and are summarized in Sill 
and von Recum [65]. The voltage of the polymer solution and collecting surface are important 
parameters for generating a sufficient electric field, and increasing the voltage sources can 
decrease fiber diameter [51]. Increasing the flow rate of the polymer solution results in an 
increase in fiber diameter. Fiber diameter can also be increased with an increase in polymer 
concentration and consequential increase in solution viscosity. Increasing the distance between 
the tip of the capillary and collecting surface results in a decrease in fiber diameter [51]. Finally, 
microtexture on the fibers can be created by increasing solvent volatility [65]. 
Tissue engineered scaffolds are often made of multiple biomaterials, and the capillary 
nozzle configuration can be adjusted for either single or multiple polymer streams during the 
electrospinning process. Three main spinneret configurations include: single capillary, dual 
capillaries, and co-axial capillaries. Single capillary technique, the most frequently employed, is 
used in fabrications in which a solution consists of a single polymer [51] or a blend of miscible 
polymers [69-71]. Dual capillaries can be set in a side-by-side configuration, to combine two 
separate polymer streams from adjacent capillaries into a single jet [65], or independently, where 
two jets form and deposit on the collecting surface [72, 73]. Coaxial configuration is another 
approach which positions one capillary inside another and allows for the entrapment of smaller 
fibers in the polymer stream [65]. 
Control of the fabricated scaffold geometry exists through the type of collecting surface 
on which the polymer is deposited. These collecting surfaces range from solid surfaces where 
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fibers can directly deposit to wire and edges between which fibers forms; other methods use ring 
structures of similar polarity to the polymer to direct the assembly of fibers [74]. When the 
collecting surface performs dynamic motions like rotation, it is often referred to as a mandrel. 
Translation and rotation can add extra complexity to the mandrel and assist in fiber deposition. 
The rotating drum is one of the more common mandrels used for generating flat scaffolds and 
has shown the ability to produce diverse scaffold properties based on the rotational and 
translational speeds [67, 68]. D’Amore et al. [51] introduced a new mandrel with a complex 
geometry using a double component deposition (DCD) technique. 
The various types of materials which can be electrospun into scaffolds provide users with 
another level of control in scaffold design. Current electrospun scaffolds for tissue engineering 
applications are derived from either natural and synthetic polymers, and recent approaches have 
used synthetic copolymers, blended natural polymers, blended synthetic polymers, and blended 
natural and synthetic polymers [75]. Natural polymers, such as proteins, polysaccharides, DNA, 
and lipids, benefit from a decreased immune response and increased biocompatibility [75], with 
collagen being the most frequently employed [65]. In contrast, synthetic materials are cheaper 
and have properties which are more easily controlled [75]. Typical synthetic polymers used in 
electrospinning include PCL, PEG, PGA, poly(lactic acid) (PLA), PLGA, and poly(L-lactide-co-
ϵ-caprolactone) (PLCL) [65, 75] as well as a variety of polyurethanes [51, 76]. 
The main drawback of scaffolds produced by electrospinning is the low porosity with 
smaller pore size and less interconnected pores. Additionally, the fabrication method produces 
sample to sample variability and is more difficult to scale up for larger production, especially for 
more complex constructs like heart valves which are produced one at a time. However, the 
ability to produce submicron diameter fibers is a major benefit of electrospinning, as these fibers 
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are close to the physiologically relevant range. The fibrous structure produces robust mechanical 
properties by achieving relevant fiber alignment and intersection density. In addition, 
electrospinning is a fairly inexpensive technique for quick prototyping and production. 
1.3.3 Electrospun scaffolds for tissue engineered heart valves 
Having the ability to control fiber diameter, scaffold geometry, mechanical response, and 
applicable polymers, electrospinning has been used in the fabrication of a number of TEHVs 
[47-51]. Van Lieshout et al. [47] used a combination of four stainless steel mandrels as collecting 
surfaces for electrospun PCL. Three of the mandrels each represented one of the valve leaflets, 
and two coatings of polymer were electrospun onto each of the pieces. The three pieces were 
then brought together with a fourth piece that had complementary geometry, and an electrospun 
layer on the outside of the assembled four-piece mandrel represented the aortic root. Del Gaudio 
et al. [48] used a single aluminum mandrel with a complex geometry to collect PCL during 
electrospinning. However, the mandrel was rotated at a very low velocity which did not provide 
fiber alignment and anisotropy. 
Tseng et al. [49] used a flat copper collector and an aluminum drum to collect PCL 
isotropic and anisotropic fibers, respectively. These constructs were added into PEG hydrogels 
and seeded with valvular interstitial cells. Although aligned fibers were produced in this study, 
the simple collecting surfaces did not produce a scaffold with anatomical geometry. D’Amore et 
al. [51] produced fully assembled, trileaflet valves from electrospun poly(ester urethane)urea 
using a double component collecting surface and complex geometry. Modification of the 
electrospinning parameters demonstrated control over the mechanical properties and fiber 
diameter of the engineered valve. Kluin et al. [50] electrospun bis-urea-modified polycarbonate 
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into a tube with aligned fibers, and a support ring made from polyether ether ketone was added to 
the construct. This acellular scaffold was implanted for up to 12 months in ovine and 
demonstrated the ability to degrade at a rate equivalent to ECM formation. 
1.4 POLYMERS FOR TISSUE ENGINEERED SCAFFOLDS 
Synthetic polymers are often used in TEHVs because they do not require a donor tissue source 
and the properties of the polymer are well known and have been extensively characterized. A 
number of factors can be controlled in the design on polymers including: copolymerization, 
molecular weight, stereospecificity, branching, cross-linking, and biodegradability. The 
degradability depends on the chemistry of the polymer and is determined by the number and type 
of labile bonds as well as the hydrophilicity of the molecule. 
1.4.1 Nondegradable polymers 
Nondegradable polymers are used in a number of medical applications [77],  but are undesirable 
and counterproductive in tissue engineering. Medical products made from nondegradable 
polymers such as polyethylene (PE), polypropylene (PP), and polysulfone include catheters, 
sutures, and hollow fibers, respectively [77]. Other nondegradable polymers like 
polytetrafluoroethylene (PTFE) and polyurethanes are used as materials in vascular grafts [78] 
and heart valves [79]. These polymers are expected to last for much longer periods of time than 
would be required for a degradable tissue engineered scaffold. 
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1.4.2 Degradable polymers 
Polymers with anhydride, ester, or amide groups are often thought of as degradable. 
Polyanhydrides are very susceptible to degradation due to the labile anhydride bonds and have 
very fast degradation rates [63]. Therefore, the hydrolysable bonds in polyanhydrides cause them 
to undergo surface degradation which makes them a good source for drug delivery [80]. 
Polyesters have longer degradation times than polyanhydrides, but still degrade on a 
relatively quick timescale making them suitable for tissue scaffolds. PGA, PLA, and PCL are a 
few examples of frequently used polyesters in tissue engineering. For TEHV applications, PGA 
[35, 36, 39, 41, 42], PLGA [37], PLC [29, 47-49], P4HB [30, 39, 41, 42], PHA [38], and PET 
[43] have all been used in. Difference in degradation rates of these polymers depend on the 
hydrophobicity and length of the carbon chain in the polymer backbone. Polyamides degrade 
much slower than polyesters [63] and have chemistry similar to proteins with variation in the R-
group. These polyamides, or polyaminoacids, are susceptible to degradation at the peptide bond. 
Other polymers which could potentially degrade but are less susceptible include 
polycarbonates and polyurethanes. Polycarbonates have also been used in TEHVs [44, 50] and 
polyurethanes will be discussed in more detail in the next section.  
1.4.3 Degradable polyurethanes 
The variable chemical, mechanical, and biological properties make polyurethanes excellent 
materials for medical and tissue engineered products [81]. Polyurethanes, which are typically 
nondegradable, have been used in a number of cardiovascular soft tissue applications including 
cardiac patches [76, 82], vascular grafts [83, 84], and heart valves [51]. To achieve 
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biodegradability, polyurethanes were modified to incorporate soft segments with labile bonds 
into their backbone. Alternating hard and soft segments in the polyurethane provided both 
flexibility and degradability for the polymer. These linear elastic polyurethanes were formed 
from the synthesis of polyester, polyether, or polycarbonate soft segments, diisocyanate hard 
segments, and a chain extender. 
Guan et al. [85] introduced poly(ester urethane)urea (PEUU) with PCL as the labile 
segment. Switching or copolymerizing the soft segment in PEUU allows for variations of the 
degradation rate. Guan et al. [86] increased the rate of degradation with the addition of PEG to 
form poly(ether ester urethane)urea (PEEUU), while Hong et al. [64] slowed the degradation rate 
by adding poly(1,6-hexamethylene carbonate) (PHC) to form poly(ester carbonate urethane)urea 
(PECUU). Other attempts [87-89] to slow degradation incorporated poly(trimethylene carbonate) 
soft segments into the polyurethane backbone. To further increase degradability, Guan et al. [90] 
adopted Ala-Ala-Lys (AAK) as the chain extender to add elastase lability to the polyurethane. 
Changing the ratios of the soft segments during synthesis allows for tuning of the 
degradation rate as well as other properties. As the ratio of polyester to polycarbonate decreased, 
the degradation rate decreased [64]. At the two extremes, PEUU degraded significantly faster 
and was mechanically stronger than PCUU while PCUU was less viscous and less thrombogenic 
than PEUU. Figure 5 is a representation of the bonding between the soft segments, hard 
segments, and chain extenders for PEUU, PCUU, and PECUU. 
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Figure 5. Representative polymer chain segments of the biodegradable polyurethanes showing soft segments 
(polyester and polycarbonate), hard segments (BDI), and chain extended (putrescine) and the urethane and urea 
bonds. A) poly(ester urethane)urea (PEUU), B) poly(carbonate urethane)urea (PCUU), and C) poly(ester carbonate 
urethane)urea (PECUU). 
 
1.5 DEGRADATION OF POLYMER SCAFFOLDS 
Degradability is a major component of most tissue engineered scaffolds as these constructs are 
designed to degrade and be replaced by new tissue at the site of application. Scaffolds with 
biodegradable polymers avoid additional surgeries to remove temporary support and prevent 
infection from a permanent scaffold. Understanding the ability of the scaffold to degrade, the 
time frame for degradation, the mechanisms through which the scaffold is broken down, and the 
products of degradation are critical in the selection of materials. Inappropriate degradation rates 
or the release of toxic products during degradation can be extremely harmful in the local 
environment of the body [91]. 
Biodegradation and bioerosion are common terms used to describe the breakdown of a 
biological scaffold. Although they are often used interchangeably, bioerosion typically involves 
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the passive breakdown of a substance through the loss of monomers and oligomers while 
biodegradation is a more active form of the breakdown and results from polymer chain scission 
[63]. All materials degrade over time, but it is the time-scale on which these materials degrade 
that define them as degradable or nondegradable polymers [63]. 
Degradation rates which do not coincide with new tissue formation can have detrimental 
effects. Fast degradation times can lead to a failure in proper stress transfer which results in 
mechanical failure, while slow degradation times (or no degradation at all) could result in 
inadequate tissue formation or fibrosis [64, 92]. In addition, degradation of a polymer chain 
results in the formation of new, smaller products with different chemistries which may be toxic 
in the body [63]. Depending on the molecular weight of the degradation product, toxic buildup in 
the kidney is possible. Consequently, in vitro or in vivo degradation studies are often performed 
on a material before employing that material in a long term preclinical study. 
1.5.1 Mechanisms of degradation 
Polymers have a number of different degradation mechanisms which include chemical, 
mechanical, oxidative, thermal, and photo degradation [63]. Ultraviolet (UV) light and γ-
radiation, both relevant for sterilization, can cause photodegradation of a polymer. Thermal 
degradation is important when processing or working with polymers at high temperatures as free 
radicals can form. High temperatures can also play a role in oxidative degradation, where oxygen 
from the atmosphere attacks the polymer at a carbon-carbon double bond. Stresses within a 
polymer scaffold, such as those in a dynamic environment, can cause mechanical degradation. A 
study by Li et al. [93] of electrospun PLGA scaffolds found increased degradation with tensile 
 25 
loading. Chemical degradation results from hydrolysis of hydrolysable bonds in a polymer [63]. 
Enzymes are used in enzymolysis to catalyze a hydrolysis reaction. 
Polymer scaffold degradation typically ranges from surface to bulk degradation, with 
specific polymer constructs typically existing somewhere between the two extremes. With 
surface degradation, scaffolds only lose polymer at the surface; over time, the volume of the 
scaffold decreases, but the shape is maintained. Conversely, bulk degradation is when the 
degrading agents can penetrate the scaffold and form fractures throughout, yet maintain the 
original shape and volume for some time [63]. Molecular weight of the polymer initially 
decreases due to chain scission, but the mass of the scaffold is maintained for a longer time until 
the fragments are washed away. 
Degradation typically occurs by cleaving bonds in the backbone of the polymer, although 
it is possible for cleavage of cross-links or side chains. With regard to backbone chemistry, 
polyanhydrides degrade faster than polyesters which degrade faster than polyamides [63]. Figure 
6 shows the general hydrolysis reaction of polyanhydrides. The hydrolysis of polyesters and 
polycarbonates (e.g. the soft segments in PECUU) is in Figure 7 and Figure 8, respectively [94]. 
Polyesters are more susceptible to acid-hydrolysis whereas polycarbonates are more vulnerable 
to alkaline-hydrolysis. Therefore, production of carboxylic acid in polyester hydrolysis results in 
a positive feedback loop for degradation. This is not the case with polycarbonates which yield 
CO2 and a molecule with hydroxyl groups on the ends [94].
 
 
 
Figure 6. General hydrolysis reaction of polyanhydrides. 
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Figure 7. General hydrolysis reaction of polyesters. 
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Figure 8. General hydrolysis reaction of polycarbonates. 
 
1.5.2 Degradation of polymer scaffolds 
There are a number of factors which can influence the degradation of a polymer scaffold, often 
involving the ability of water or solution to access the polymer. The hydrophobicity or 
hydrophilicity of the surrounding groups affects the ability of the polymer to take-up water and 
alters the degradation time [63, 95]. Less crystalline and amorphous polymers degrade at a faster 
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rate than highly crystalline polymers [95, 96]. As would be expected, polymers that start off at a 
lower molecular weight will degrade faster. 
Scaffold surface area also influences degradation rate as larger surface to volume ratios 
lead to faster degradation. This is influenced by scaffold geometry and the fabrication method, as 
electrospinning produces fibers that result in a large surface area [95]. Finally, as mentioned 
above, mechanical stresses on the polymer scaffold can increase the degradation rate [63, 95]. In 
vivo, the local environment can also affect degradation; cells, pH, and enzymes can all increase 
the degradation rate of scaffolds [95]. 
Scaffolds are often designed to degrade by certain enzymes or processes. A study by 
West and Hubbell [97] used ABA block copolymers with oligopeptides capped with acrylate 
groups as the A block and PEG as the B block. Crosslinking via photopolymerization was used 
to created hydrogels which could be degraded by collagenase and plasmin. Further work by 
Lutolf et al. [98] studied proteolytic degradation with matrix metalloproteinases of hydrogel 
scaffolds based on the oligopeptide amino acid sequence from end-functionalized PEG and how 
the degraded hydrogel affected cell infiltration. 
1.5.3 Enzymatic degradation 
Many studies have been conducted to characterize the degradation of polyurethanes with a 
number of different variations including backbone chemistry [64, 82, 85, 90, 99], polymer 
concentrations [66, 100], collagen/ECM concentrations [101, 102], surface modification [86, 
103], functionalization [104, 105], growth factor loading [106], and stent coatings [107]. In vitro 
testing in phosphate buffered saline (PBS) [64, 85-87, 100, 102, 103, 106, 108] is a relatively 
inexpensive method to find comparative degradation rates between different polymers, but 
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degradation is more time intensive due the absence of many environmental factors (e.g. 
mechanical stress, enzymes, cells). In vivo testing in an animal model [64, 82] evaluates a 
polymer scaffold in the native environment producing faster and more accurate degradation 
rates, but is more cost intensive. Accelerated degradation, an alternative to these two methods, 
performs degradation analysis in vitro using an enzyme solution [66, 90, 99, 101, 104, 105, 107] 
to increase the degradation rate and more accurately recapitulate the native environment. While 
this method will not exactly replicate the in vivo degradation, it provides a more accurate 
representation of how a polymer scaffold will perform in the body. 
The benefits of accelerated degradation with enzymes in vitro make it a useful method for 
evaluating biodegradable scaffolds. Several studies [66, 90, 101] have shown a significant 
increase in degradation rate when employing an enzyme as opposed to only using PBS. Polymers 
will respond to specific enzymes based on their chemistry, and scission of the backbone, cross-
links, or side groups can be controlled. Because of this specificity, in vitro experiments have 
adopted a number of different enzymes to analyze polymer scaffold degradation. These enzymes 
include elastase [90], collagenase [101], and lipase [66, 99, 104, 105, 107] which break down 
proteins, collagen, and lipids, respectively. Specifically, lipase is a type of esterase which 
catalyzes the hydrolysis of a labile ester bonds. Thus, the possibility exists to tailor the polymer 
chemistry with an enzyme specific functional group to control degradation. 
1.5.4 Degradation of tissue engineered heart valves 
A TEHV is intended to act as a temporary mechanical support and scaffold for cell attachment. 
Providing a scaffold on which cells can proliferate, differentiate, and produce ECM [92] is 
critical to generating new functional tissue. Understanding and controlling the degradation rate is 
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critical in the design of the scaffold materials, and degradation rate should be matched to rate of 
new ECM production on the scaffold. If the degradation is too fast, the valve could fail 
mechanically due to inadequate tissue formation; leaflet stiffening and the inability for proper 
coaptation can result from slow degradation [92]. 
Initial approaches to engineered heart valves used biodegradable polymers with rapid 
degradation rates like PGA and P4HB [35-37, 39-41]. Hoerstrup et al. [40] determined total 
degradation time for these two polymers to be 4 and 8 weeks, respectively, in the valve 
construct. Other early work by Sodian et al. [38] found polyhydroxyoctanoate (PHO) to have a 
longer degradation period as scaffolds explants from in vivo studies still had scaffold present at 
17 weeks. More recent attempts [47-49] have used PCL to increase the degradation time and 
prevent mechanical failure. Although each of these studies utilize known biodegradable 
polymers, degradation rates were not extensively studied to analyze the effect of multiple 
polymers, valve position, cell type, etc. 
Recent studies involving TEHVs have included characterization of material degradation 
rates. Badrossamay et al. [29] studied the degradation rate of different combinations of PCL with 
collagen or gelatin. Degradation and the corresponding mechanical properties were studied for 
the bis-urea-modified polycarbonate leaflets presented in Kluin et al. [50]. Furthermore, Sant et 
al. [109] studied the degradation of blended poly(glycerol sebacate) (PGS) and PCL, and 
specifically analyzed the interplay between scaffold degradation, ECM synthesis, and 
mechanical properties. The addition of the faster degrading PGS led to a slight decrease in the 
mechanical properties of the scaffolds. 
Brugmans et al. [110] studied the effects that the slower degrading PCL had on valve 
leaflet retraction as compared to PLA/P4HB. After culturing the polymer scaffolds with cells for 
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4 weeks, PCL scaffolds showed significantly less retraction, which would lead to less 
regurgitation in the valve construct. Additionally, Brugmans et al. [111] cultured the PCL and 
PLA/P4HB scaffolds as cellular and acellular constructs. In the acellular scaffolds, PLA/P4HB 
degraded significantly faster than PCL. Cellular scaffolds demonstrated tissue growth in both 
groups, with PLA/P4HB scaffolds generating slightly more initial tissue, but at the end of the 
study, PCL scaffolds produced more total tissue. 
Reimer et al. [33] fatigued a TEHV in a pulse duplicator for 2 weeks to evaluate the 
effects of the mechanical stresses experienced by heart valves. The stentless construct showed no 
significant tearing in the valve or valve leaflet after more than 2 million cycles. There is a need 
for biodegradable TEHVs within the pediatric population, and understanding the degradation 
rates and new tissue formation is important in the design. Tunable elastomers provide the 
possibility of controlling degradation rates in TEHVs [92]. Segmented polyurethanes [64, 85, 86] 
provide this ability and can be electrospun into scaffolds with controllable fiber populations and 
mechanical properties [51, 67, 68, 112] providing the possibility of creating an entire valve 
construct with appropriate mechanics, function, and degradation. 
1.6 MIXING OF POLYMERS IN ELECTROSPUN SCAFFOLDS 
Polymer scaffolds often combine polymers with different properties to achieve desired 
characteristics of the scaffolds such as appropriate degradability, mechanics, and blood 
compatibility. Additionally, natural materials are often integrated into the synthetic scaffold 
through electrospinning to increase the biocompatibility [113]. This combination of polymers 
can be achieved several different ways: bonding the scaffolds together during synthesis to form a 
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copolymer, blending miscible polymers together in a solvent to form a single solution, or 
electrospinning different streams of polymers together into a scaffold. 
1.6.1 Copolymerization 
Copolymerization is a synthesis technique which combines multiple units together into a single 
chemical structure. Depending on the form of synthesis, the copolymers could have a random, 
alternating, block, or graft structure. PLGA is a frequently used copolymer in biomaterials 
applications and is used in products approved by the Food and Drug Administration (FDA). 
Zund et al. [37] used a PLGA copolymer woven mesh in the design of a TEHV. For designed 
drug release, different ratios of lactic and glycolic acid in the PLGA copolymer can control the 
release profile of drugs [114]. 
Polyurethanes with soft segments can be used to generate a desired response within a 
polymer. Guan et al. [86] used PCL and PEG to produce PEEUU, a triblock copolymer, with 
tunable degradation rates. Likewise, Hong et al. [64] incorporated PCL and PHC into the 
polyurethane backbone to produce variations of PECUU with slower degradation rates. The 
scaffold with the moderate degradation rate, 50/50 PECUU, was found to be optimal by 
Hashizume et al. [82] during an in vivo study with a temporary cardiac patch. 
1.6.2 Polymer blends 
Polymer blending is the physical mixing of two independent polymers together into a solvent to 
form a single polymer solution. A solvent which can dissolve all of the selected polymers is 
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required for this process. This approach is a common way of combining natural and synthetic 
polymers into an electrospun scaffold. 
In TEHV applications, PCL was blended with collagen or gelatin in varying ratios in a 
solvent before rotary jet spinning [29]. Similarly, P4HB and gelatin were blended at different 
ratios with the same production process [30]. Blends of P4HB, chitosan, and fibroblast growth 
factor were electrospun onto decellularized porcine aortic valve leaflets [115]. Hinderer et al. 
[69] blended PEG dimethacrylate and PLA in solvent before electrospinning into a heart valve 
using a custom device. Likewise, Sant et al. [70] electrospun blends of PGS and PCL at various 
ratios. 
There have also been applications of polyurethane blends with natural materials to form 
small diameter vascular grafts. Wang et al. [71] electrospun blends of polyurethane and PEG into 
vascular grafts with increased blood compatibility due to the PEG incorporation. Thermoplastic 
polyurethane was blended with collagen and chitosan in Huang et al. [116] and electrospun into 
vascular grafts. Furthermore, Hong et al. [84] blended PEUU with 2-methacryloyloxyethyl 
phosphorylcholine (MPC) to form a vascular graft by electrospinning the blended solution. 
1.6.3 Dual-stream electrospinning 
Dual-stream electrospinning utilizes two independent polymer solutions to create two streams of 
polymer fibers being deposited on the collecting surface. Scaffolds produced with this method 
have two independent fiber populations intertwined in the scaffold. This technique can be 
applied to polymers which do not dissolve in similar solvents and need to be combined in a 
scaffold [65]. Gupta and Wilkes [117] electrospun two polymer solutions onto a collector using a 
bicomponent technique where the two polymer solutions were adjacent to one another. Mixing 
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electrospinning was introduced by Kidoaki et al. [72] who deposited polyurethane and 
poly(ethylene oxide) (PEO) on a rotating mandrel to create a mesh with mixed fibers. 
Multiple jet configurations were studied by Theron et al. [118] through experimental and 
modeling analysis with a single polymer, PEO. A multicomponent electrospinning setup in Ding 
et al. [119] presented different ratios of electrospinning jets producing polymer poly(vinyl 
alcohol) and cellulose acetate. A scaffold with sacrificial fibers was co-electrospun in Baker et 
al. [73] from PCL and PEO, and the PEO fibers were removed by submerging the scaffolds in 
water following the fabrication.   
The presence of multiple capillary tubes with similar polarities close to one another may 
influence the electric field and electrospinning jet [74]; therefore, positioning the capillaries on 
opposite sides of the rotating mandrel can limit this problem. The dual-stream process has been 
applied to electrospraying as well to create scaffolds with combinations of synthetic polymers 
and cell culture medium [120], cells [121], and ECM [76]. 
1.7 STUDY RATIONALE 
1.7.1 Purpose of this study 
A novel TEHV and fabrication method was introduced by D’Amore et al. [51] to overcome 
many of the obstacles faced by prosthetic heart valves as well as other TEHVs. Biodegradable, 
elastomeric, trileaflet heart valves were produced as fully assembled constructs without a stent. 
The acellular structures were designed to have appropriate geometry, corresponding mechanical 
properties, and similar fiber diameter to a native heart valve. 
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To de-risk the first preclinical studies, the valve should be tailored toward a lower 
pressure location (e.g. the right side of the heart in the tricuspid or pulmonary position). With an 
interest in the atrioventricular valves, the tricuspid valve was selected due to the lower 
transvalvular pressure [15]. Although the incidence with the tricuspid valve is much lower than 
the mitral valve [1], initial in vivo assessment should evaluate the valve in the tricuspid position. 
Acellular TEHVs are designed to recruit endogenous cells from the body to support 
endogenous tissue growth in situ [50]. Using the body as a bioreactor to support new ECM 
production, the degradation rate of the scaffold should match that of the new tissue formation in 
order to avoid detrimental effects [92]. Figure 9 shows the desired response from an acellular 
valve where endogenous cells populate the scaffold and remodel. Matching rates of material 
degradation and formation will allow for appropriate stress transfer and avoid mechanical failure 
or fibrosis at the site [64].  
 
 
Figure 9. Desired response of an acellular TEHV which relies on endogenous cells for new tissue growth and 
remodeling (from [50]). 
 
This study is intended to investigate the degradation rates and corresponding changes in 
mechanical properties of electrospun TEHVs produced with the three mixing strategies 
introduced in Section 1.6. These strategies could potentially provide tunable degradation rates of 
the biodegradable heart valves based on the polyurethane soft segment mixing strategy. For in 
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vivo preclinical studies, TEHV degradation rates can be matched to the new tissue formation in 
order to prevent mechanical failure in the animal. 
1.7.2 Study design 
An accelerated in vitro degradation study was designed to evaluate the degradation rates of 
biodegradable polyurethanes using the three mixing strategies. Incorporating polyester and 
polycarbonate soft segment into the backbone of polyurethanes has been shown to change the 
degradation rate [64, 99]; an increase in polycarbonate segments decreases the degradation rate. 
This study will consider a 50/50 ratio of polyester to polycarbonate soft segments combined in 
three different ways, shown in Figure 10. The soft segment mixed (chemical) TEHV group was 
formed by synthesizing a mixture of polyester and polycarbonate segments into the backbone of 
polyurethane urea to form PECUU, dissolving the polymer in HFIP, and electrospinning heart 
valves using a single polymer stream. The physically blended TEHV group was formed by 
synthesizing PEUU and PCUU by incorporating polyester and polycarbonate segments, 
respectively, into the polyurethane urea backbone, dissolving the PEUU and PCUU together in 
HFIP, and electrospinning using a single polymer stream. The co-stream electrospun TEHV 
group was formed by dissolving PEUU and PCUU in HFIP in separate solutions and 
electrospinning using two polymer streams. A depiction of the polymer chain and fiber 
composition for the three mixing strategies is shown in Figure 11. The soft segment mixed 
group should have polymer chains consisting of both polyester and polycarbonate soft segments 
in all electrospun fibers. The physically blended group should have individual polymer chains of 
either polyester or polycarbonate soft segments, but the electrospun fibers should have both soft 
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segments. The co-spun group should have polymer chains with either polyester or polycarbonate 
soft segments and each fiber should only contain either polyester or polycarbonate soft segments. 
 
 
Figure 10. Schematic of polyurethane soft segment mixing strategies: soft segment mixing (chemical), physical 
blending (blended), and co-stream electrospinning (co-spun). 
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Figure 11. Depiction of the polymer chain and electrospun fiber composition for the three mixing strategies where 
red represents the polyester segments and blue represents the polycarbonate segments. 
 
An accelerated degradation study was performed on TEHVs from the three mixing 
strategies to more accurately represent the in vivo environment. Hydrolytic, enzymatic, and 
mechanical degradation were performed on the TEHVs by using a lipase/PBS solution in a pulse 
duplicator shown in Figure 12. The results of lipase in degradation studies has been shown in 
[66, 99, 104, 105], and to evaluate the degradation effect of pulsatile mechanical forces, a 
comparison study was completed on a rocker with a lipase/PBS solution. Degradation of the 
TEHVs was performed for up to 2 weeks in the pulse duplicator [33]. Valve mass, leaflet 
thickness, surface morphology, mechanical response, and polymer viscosity were evaluated 
throughout the study to determine the effects of degradation. Additionally, blood compatibility 
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was considered for the three mixing strategies to assess if the polymer chemistry or fiber 
population had a significant effect. 
 
 
Figure 12. Pulse duplicator and schematic. A) Pulse duplicator for the accelerated degradation study with tissue 
engineered heart valves. B) Valve holder with the valve positioning apparatus. C) Schematic of the pulse duplicator 
layout. 
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1.8 OBJECTIVES 
1.8.1 Objective #1: Characterize the degradation profile of engineered polyurethane 
heart valves with variable soft segment mixing strategies 
As discussed previously, tissue engineered scaffolds are often produced from multiple polymers 
combined through copolymerization, blending, or dual-stream electrospinning to attain desirable 
performance. To our knowledge, there has not been a comparative study evaluating these three 
combination methods. Therefore, the first objective in this study is to characterize the 
degradation profile of each mixing strategy applied to a biodegradable TEHV in a mechanically 
demanding environment. 
1.8.2 Objective #2: Determine the effect of a mechanically demanding and dynamic 
environment on the degradation rate 
Polymers can undergo numerous types of degradation (e.g. mechanical, chemical, thermal) 
simultaneously, but most in vitro degradation studies only consider hydrolytic or enzymatic 
degradation. Since a TEHV will undergo cyclical mechanical stress in vivo, degradation studies 
should be extended to consider mechanical degradation as well in order to more accurately 
represent the native environment. The next objective in this study is to evaluate the effect a 
mechanically demanding environment has on a TEHV with respect to a valve leaflet without 
mechanical loading. 
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1.8.3 Objective #3: Investigate the mechanical properties of the engineered heart valves 
following degradation 
Degradable tissue engineered scaffolds should mechanically support damaged tissue while new 
tissue forms. Ideally, the rate of scaffold degradation and new tissue formation should be 
equivalent for proper stress transfer from the scaffold to the new tissue. Fast degradation rates of 
the scaffold and corresponding mechanical properties can lead to mechanical failure at the site of 
the scaffold. In this objective, the intent is to investigate if and how the in-plane mechanical 
properties of the TEHV change during degradation. 
1.8.4 Objective #4: Determine the effects of the mixing strategies on blood compatibility 
Tissue engineered scaffolds in applications with continuous blood contact should have sufficient 
blood compatibility in order to minimize the chance of thrombus formation. Although polymer 
chemistry has been shown to affect the blood compatibility, this study uses an equivalent amount 
of each polyurethane soft segment. The mixing strategies combine these segments in three 
different ways, altering the composition of the scaffold fibers. This final objective is meant to 
investigate the mixing strategies, which produce polymer chains and fibers with different 
chemistries, on blood compatibility. 
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2.0  MATERIALS AND METHODS 
2.1 MATERIALS 
Polycaprolactone diol (PCL diol, Mn = ~2,000 g/mol, Sigma, Burlington, MA) and 
poly(hexamethylene carbonate) diol (PHC diol, Mn = ~2,000 g/mol, Scientific Polymer Products, 
Ontario, NY) were dried using toluene distillation prior to use. Putrescine (Sigma) and 1,4-
diisocyanatobutane (BDI, Sigma) were purified with vacuum distillation. Anhydrous toluene 
(Sigma), anhydrous dimethyl sulfoxide (DMSO, Sigma), tin(II) 2-ethylhexanoate (Sn(Oct)2, 
Sigma), 2-propanol (Sigma), and 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP, Oakwood Chemical, 
Estill, SC) were used as received. Phosphate buffered saline (PBS) tablets (Sigma) were 
dissolved in deionized water to form a 1x PBS solution. Lipase from porcine pancreas (Sigma) 
was used as received. 
2.2 POLYURETHANE SYNTHESIS 
Biodegradable polyurethanes elastomers were synthesized using a two-step polymerization 
process shown in Figure 13. Prior to synthesis, BDI and putrescine were vacuum distilled to 
remove any remaining impurities. Poly(ester urethane)urea (PEUU), poly(carbonate 
urethane)urea (PCUU), and poly(ester carbonate urethane)urea (PECUU) were synthesized using 
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PCL diol and/or PHC diol as the soft segment, BDI as the hard segment, and putrescine as the 
chain extender. The ratio of (PCL diol):(PHC diol) in the synthesis of PEUU, PECUU, and 
PCUU were 100:0, 50:50, and 0:100, respectively. A 1:2:1 molar ratio of (PCL diol/PHC 
diol):BDI:putrescine was used in the synthesis as reported in Hong et al. [64]. In the first 
polymerization step, diol was added to a triple-neck flask and dried using toluene distillation 
with a vacuum pump. Anhydrous DMSO was then added to the diol and the flask was 
submerged in an oil bath with argon protection. BDI was added dropwise to the flask followed 
by six drops of Sn(Oct)2. After reacting for 3 hours at 70°C, the prepolymer solution was cooled 
to room temperature. Next, putrescine mixed with DMSO was slowly added dropwise to the 
prepolymer solution with constant stirring. This chain extension reaction proceeded overnight at 
50°C. An excess volume of cool deionized water was used for polymer precipitation. Finally, the 
polymer underwent multiple water exchanges to remove any remaining solvent, followed by a 
wash with 2-propanol, before drying for 2 days in a vacuum oven at 50°C. 
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Figure 13. Two-step polyurethane synthesis schematic for PEUU. The same two-step polyurethane synthesis 
schematic was used for PCUU and PECUU by exchanging the PCL diol for PHC diol or PCL diol/PHC diol, 
respectively. 
 
2.3 TISSUE ENGINEERED HEART VALVE SCAFFOLD FABRICATION 
Fully assembled, stentless, trileaflet heart valves were fabricated by an electrospinning process, 
described in Section 1.3, to deposit biodegradable polyurethanes onto a rotating mandrel (i.e. 
collecting surface) developed by D’Amore et al. [51]. Briefly, the mandrel shown in Figure 14, 
was designed in SolidWorks (Dassault Systèmes, Vélizy-Villacoublay, France) and consisted of 
two components: a conductive aluminum alloy machined into the shape of a heart valve and a 
non-conductive acrylonitrile butadiene styrene (ABS) shield produced by injection molding. This 
double component deposition (DCD) technique exploits the differences in the material 
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conductivities to selectively redirect fiber deposition to more inaccessible areas on a complex 
surface geometry.  
 
 
Figure 14. Double component deposition (DCD) mandrel for electrospinning heart valves. A) SolidWorks drawing 
of the assembly, B) assembled DCD mandrel, and C) mandrel with deposited electrospun fibers. 
 
Experimental groups combined polyester and polycarbonate soft segments into a 
polyurethane by three different mixing strategies. Soft segment mixed valves were produced 
through electrospinning a 12% w/v PECUU in HFIP solution; physically blended valves were 
produced by dissolving 6% w/v PEUU and 6% w/v PCUU together in HFIP and electrospinning 
a single solution; and co-stream electrospun valves were produced via two independent streams 
of 12% w/v PEUU in HFIP and 12% w/v PCUU in HFIP. A schematic of the one- and two-
stream electrospinning setup is shown in Figure 15 with high voltage power sources (Gamma 
High Voltage Research, Ormond Beach, FL), syringe pumps (Harvard Apparatus, Holliston, 
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MA), stepper motor (Oriental Motor, Tokyo, Japan) for rotation, and stepper motor (Velmex, 
Bloomfield, NY) for rastering. Each polyurethane group was dissolved in HFIP overnight at an 
equivalent concentration of 12% w/v. The mandrel was rotated at 250 rpm and polymer 
deposition was concentrated on the conductive leaflets by limiting the rastering span to 3.5 cm. 
Each polymer solution was loaded into a 10 mL syringe (Becton Dickinson, Franklin Lakes, NJ), 
and the conditions for electrodeposition were: polymer flow rate of 1.5 mL/hr, polymer voltage 
of +12 kV, gap distance of 4.5 cm, and mandrel voltage of -5 kV.  
 
 
Figure 15. Schematic of the electrospinning setup for A) one-stream and B) two-stream fabrications. 
 
Valve scaffold thickness was controlled by polymer deposition time and was targeted for 
the reported native porcine tricuspid valve thickness of 227 μm [51]. Polymer deposition was 
studied for each experimental group by electrospinning valves at three different time points for 
up to 4 hours, performing a linear interpolation of the polymer dipositive vs. time, and 
calculating the required deposition time to achieve a thickness of 227 μm. Electrospun heart 
valves were then fabricated using the calculated deposition time for each experimental group. 
Video 1 in the supplemental materials is an example of the TEHV electrospinning setup, 
deposition process, and removal from the mandrel. 
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2.4 PULSE DUPLICATOR DESIGN 
A custom designed pulse duplicator [51] was used to test the degradation rates of the engineered 
heart valves under mechanical stresses. Modifications were made to the system to allow for 
control over the fluid temperature, with the new setup shown in Figure 12. Electrospun valves 
(Figure 16A) were prepared for testing by using Ti-Cron™ 0 braided polyester sutures 
(Medtronic, Minneapolis, MN) to suture along each commissure and create ~1 cm loop at the top 
(Figure 16B). Another ~2 cm loop was tied between each initial loop and one of the three 
equally-spaced stainless steel posts (Figure 16C) to function as chordae tendineae for an 
atrioventricular valve in the native heart before loading into the valve holder (Figure 16D). A 
Thoratec® TLC-II® Portable VAD Driver (Thoratec Corporation, Pleasanton, CA) was used to 
control a Thoratec® Paracorporeal Ventricular Assist Device (PVAD, Thoratec Corporation) 
which generated pulsatile flow across the valve. The PVAD functioned at 80 beats per minute 
and had a stroke volume on 65 mL. System pressure was collected from K1VAC/30PSI sealed 
SS compound transducers (Cole Parmer, Vernon Hills, IL) and flow was measured with a PXL 
Clamp-on Flowsensor (11XL, Transonic Systems Inc., Ithaca, NY). A 3MP USB2.0 Microscope 
Digital Camera (AmScope) equipped with a EF 50mm f/2.5 Compact Macro Lens (Canon Inc., 
Melville, NY) faced the ventricular side of the valve positioning apparatus and recorded videos 
of the valve hemodynamic performance. A custom-made LabVIEW (National Instruments, 
Austin, TX) program was used in conjunction with a USB-6009 data acquisition (DAQ) unit 
(National Instruments) to display and record synchronized hemodynamic data and videos of 
valve motion. A SC100 Immersion Circulator (Thermo Fisher Scientific, Pittsburgh, PA) was 
combined with the compliance chamber to provide a heat source and maintain control over the 
temperature of the system.  
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Figure 16. Process of loading the valve into the pulse duplicator. A) Electrospun valve, B) valve with sutures along 
commissure with ~1 cm loop, C) valve connected to post with ~2 cm loop on valve positioning apparatus, and D) 
valve positioning apparatus loaded into the valve holder. 
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2.5 TISSUE ENGINEERED HEART VALVE ACCELERATED IN VITRO 
DEGRADATION 
Electrospun trileaflet valves were subjected to enzymatic, hydrolytic, and mechanical 
degradation in the pulsatile flow system with an enzymatic solution at physiological temperature 
for up to 2 weeks [33]. Prior to degradation, the valves were weighed and the leaflet thicknesses 
were measured. Valves were sutured to the posts as described in Section 2.3 and loaded into the 
valve holder of the pulse duplicator. Engineered valve scaffolds were immersed in 4 L of 100 
unit/mL lipase/PBS at 37°C [66, 105] and experienced pulsatile flow at 80 beats per minute. 
Enzymatic solution was changed twice per week [99, 104], momentarily stopping the pulsatile 
flow. Degraded valves were removed for evaluation at three timepoints: 3 days, 7 days, and 14 
days. Sutures in the commissures were carefully removed and valves were rinsed 3x with 
deionized water followed by 3 days of drying in a lyophilizer (Labconco, Kansas City, MO). 
To understand how mechanical loading affected the degradation rate, valve leaflets were 
also degraded in an enzymatic solution without mechanical loading. Single leaflets were excised 
from the fully assembled construct and immersed in 15 mL of 100 unit/mL lipase/PBS in 20 mL 
glass vials. Vials were slowly rocked on a rocking platform shaker (VWR Scientific, Radnor, 
PA) in an incubator (Fisher Scientific, Hampton, NH) to maintain a constant temperature of 
37°C. Timepoints, rinsing, and drying were the same as described above. 
2.5.1 Valve visual inspection 
Qualitative analysis of the degraded scaffold macrostructure was conducted to understand areas 
of significant degradation within the valve and to compare the soft segment mixing strategies. 
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An EOS Rebel T3 camera (Canon, Melville, NY) equipped with a EF-S 18–55mm lens (Canon) 
was used to photograph the assembled valve construct. A blade was used to open the valve along 
one commissure, and additional images of the atrial and ventricular surfaces of all valves were 
captured. 
2.5.2 Valve mass loss 
Mass loss was evaluated for both the mechanically loaded valves (n = 3/group/timepoint) and 
unloaded leaflets (n = 3/group/timepoint) according to [99, 104, 105]. Sample mass before 
degradation (m0) and mass following degradation and drying (m1) were recorded from a balance 
(OHAUS, Parsippany, NJ) and used to calculate mass remaining according to Equation 1: 
 
2.5.3 Leaflet thickness loss 
Leaflet thickness loss (n = 3/group/timepoint) was visualized for the mechanically loaded valves 
using an interpolation tool introduced in [51]. Leaflet thickness was measured with a dial 
indicator gage (Starrett, Athol, MA) at fifteen locations [122]: five in the belly region and ten 
distributed around the free edge, commissures, and annulus of the valve leaflet to serve as 
boundary values, as depicted in Figure 17A. Thicknesses prior to degradation (t0) and after 
drying post-degradation (t1) were used to calculate the thickness remaining with Equation 2: 
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A surface map of leaflet thickness remaining was generated using a biquintic numerical 
interpolation in MATLAB (MathWorks, Natick, MA) with a custom-made script [51]. Thickness 
loss was also quantitatively compared (n = 3/group/timepoint) for the mechanically loaded 
valves using the leaflet thickness measured at five points in the belly region with a dial indicator 
gage (Starrett) as shown in Figure 17B. Thickness measurements from each of the three leaflets 
were averaged before (t0) and after degradation (t1) and calculated according to Equation 2. 
 
 
Figure 17. Location of valve thickness measurements for A) fifteen points and B) five points. 
 
2.6 SURFACE MORPHOLOGY OF DEGRADED TISSUE ENGINEERED HEART 
VALVES 
Scanning electron microscopy (SEM) was employed to observe the surface morphology of the 
degraded valves (n = 3/group/timepoint). A small rectangle with the longer edge oriented in the 
circumferential direction of the leaflet, shown in Figure 18A, was removed from the belly region 
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of each degraded valve, slightly offset to account for leaflet tears or holes. Samples were 
attached to metal stubs with double-sided copper tape, and sputter coated with gold/palladium to 
4.5 nm before imaging with the SEM (JSM-6335F, JEOL USA, Peabody, MA) shown in Figure 
18B. Images were collected at 25x, 250x, and 1500x to qualitatively analyze surface and fiber 
characteristics of the degraded leaflets.  
 
 
Figure 18. A) Electrospun valve with a red box indicating the location of the excised piece for SEM imaging. B) 
SEM at the University of Pittsburgh, Center for Biologic Imaging (CBI) used for imaging. 
 
2.7 BIAXIAL MECHANICAL RESPONSE OF DEGRADED TISSUE ENGINEERED 
HEART VALVES 
To understand the effects of degradation on the mechanical response of the valves, biaxial 
mechanical testing was performed on the degraded leaflets (n = 3/group/timepoint) according to 
[123]. A square ranging from 6 mm x 6 mm to 10 mm x 10 mm was removed from the belly 
region of the valve leaflet (Figure 19A), and sample thickness was determined by averaging five 
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thickness measurements from a dial indicator gage (Starrett). A Sharpie was used to make four 
dots in an approximate 3 mm x 3 mm square in the middle of the sample to measure the 
deformation gradient tensor, and four hooks attached to two strings were inserted along each side 
of the sample. After loading into a biaxial testing device (Figure 19B), samples were 
preconditioned and tested in a PBS solution at room temperature for ten cycles of 15 seconds. A 
Lagrangian equi-stress protocol was used for testing to a peak stress of 400 kPa and membrane 
tension of 120 N/m, physiologically relevant values for heart valve leaflets as reported in [51, 54, 
57, 58]. Mechanical responses were post-processed with a custom-made MATLAB 
(MathWorks) script, using the free-float marker configuration following preconditioning as the 
reference state. The MATLAB script also performed strain energy calculations for the equi-stress 
test by fitting a fifth-degree polynomial to the stress-strain curve of each axis between 5 kPa and 
400 kPa and integrating the area below the polynomial equation.  
 
 
Figure 19. A) Electrospun valve with a red box indicating the location of the excised piece for biaxial mechanical 
testing. B) Biaxial testing device for in-plane mechanical characterization. 
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2.8 POLYMER VISCOSITY OF DEGRADED TISSUE ENGINEERED HEART 
VALVES 
Relative viscosity of the degraded polymer valves was measured at 21°C using an Ubbelohde 
viscometer (Ace Glass, Inc., Vineland, NJ) with the method described in [89]. Following 
degradation, the dried valve leaflets were dissolved in 15 mL of HFIP at a concentration of 0.4 
g/dL. The solution was filtered using a 10 mL syringe (Becton Dickinson) and a 0.22 μm 
polyethersulfone syringe filter (MilliporeSigma, Burlington, MA) before loading into the 
Ubbelohde viscometer. The efflux time of HFIP and each polymer solution was measured five 
times and averaged. Inherent viscosity (IV) of the polymer valves (n = 3/group/timepoint) was 
calculated from the relative polymer viscosity and the concentration of the solution with 
Equation 3: 
 
where tp is the polymer solution efflux time, ts is the HFIP efflux time, and Cp is the 
concentration of polymer solution. IV at each degradation timepoint was then normalized with 
respect to the 0 days degradation valves of that group. 
2.9 BLOOD COMPATIBILITY OF TISSUE ENGINEERED HEART VALVES 
Ovine were used as a source for whole blood which was collected by jugular venipuncture. 
Guidelines presented by the National Institute of Health (NIH) for the care and use of laboratory 
animals were observed, and the animal protocol was approved by the Institutional Animal Care 
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and Use Committee (IACUC) at the University of Pittsburgh. A simple rocking test [124] was 
used to evaluate the thrombotic deposition on the electrospun polymer surface. Whole ovine 
blood was immediately mixed with 10% sodium citrate. A punch (Acuderm, Fort Lauderdale, 
FL) was used to cut 8 mm disks from the valve leaflets. The disks were sterilized using 70% 
ethanol and placed in a Vacutainer blood collection tube (Becton Dickinson) where 5 mL of 
ovine blood was added to each tube and rocked gently on a hematology mixer (Fisher Scientific, 
Hampton, NH) for 1.5 hours at 37°C. After rocking, the samples were rinsed in DPBS 
(Dulbecco's phosphate buffered saline) 10x to remove any blood not adhering to the surface.  
Lactate dehydrogenase (LDH) assay [124] was used to quantify platelet deposition on the 
valve leaflet surface (n = 3/group) with a LDH Cytotoxicity Detection Kit (Takara Bio USA, 
Mountain View, CA). Briefly, following DPBS rinsing, samples were dried and added to vials 
filled with 500 μL Triton X solution. Whole ovine blood was centrifuged (Sorvall Legend RT, 
Thermo Fisher Scientific, Pittsburgh, PA) at 250 g for 20 minutes, and the supernatant was also 
added to a vial with Triton X solution. After 20 minutes in the Triton X solution, 500 μL of 
solution from the vials was added to an Eppendorf tube (Hauppauge, NY) and centrifuged at 250 
g for 10 minutes. For each sample, 100 μL of the supernatant was added to a 96-well plate 
(Fisher Scientific), and the supernatant of the standard was diluted to 6000k, 3000k, 600k, 300k, 
60k, 30k, and 0 platelets for the standard curve. From the kit, 11.25 mL dye was added to 250 μL 
catalyst and mixed, and 10 μL of this solution was added to each well. After reacting for one 
hour in the dark, the 96-well plate was loaded into a SpectraMax M2 microplate reader 
(Molecular Devices, San Jose, CA) and analyzed with SoftMax Pro 5 software (Molecular 
Devices). The equation from the linear interpolation of the standard curve absorbance values was 
used to determine platelet adhesion for the experimental leaflets divided by disk surface area.  
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2.10 STATISTICAL ANALYSIS 
Statistical analysis of the data was performed with SigmaPlot (Systat Software, San Jose, CA). 
All results in tables and graphs are presented as mean ± standard error of the mean. T-tests were 
used when comparing two groups, and one-way analysis of variance (ANOVA) with Tukey post-
hoc testing for multiple comparisons was applied to many groups. Differences were determined 
to be statistically significant if p < 0.05. 
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3.0  RESULTS 
3.1 POLYMER SYNTHESIS 
Biodegradable polyurethane elastomers (PEUU, PECUU, and PCUU) were synthesized with the 
two-step polymerization method. Variations in the chemistry of the three polyurethanes involved 
substitution of polyester and/or polycarbonate into the polyurethane backbone. Figure 20 shows 
the degradable PEUU, PECUU, and PCUU after synthesis and dissolved in HFIP at an 
equivalent 12% w/v for the three mixing strategies. Inherent viscosity for each polyurethane is 
listed in Table 1 and each was higher than the literature value in [64] with large variations in the 
PECUU. 
 
 
Figure 20. Synthesized A) PEUU, B) PECUU, and C) PCUU. Dissolved polyurethanes for the D) soft segment 
mixed, E) physically blended, and F) co-steam electrospun mixing strategies. 
 58 
 
Table 1. Synthesized polyurethane inherent viscosity compared to literature. 
 Inherent Viscosity 
(dL/g) 
Hong et al. [64] 
(dL/g) 
PEUU 1.42 ± 0.02 1.38 
PECUU 1.18 ± 0.25 0.96 
PCUU 1.02 ± 0.07 0.80 
 
3.2 TISSUE ENGINEERED HEART VALVE SCAFFOLD FABRICATION 
Fully assembled, stentless, trileaflet heart valves were fabricated from the biodegradable 
polyurethanes through electrodeposition onto the valve-shaped mandrel. Figure 21A-C shows 
the relationship of deposition time vs. valve leaflet thickness for each of the processing 
conditions. A desired thickness of 227 μm required 3.51 hours, 4.13 hours, and 2.46 hours of 
fabrication for the soft segment mixed, physically blended, and co-spun valves, respectively. 
There was no significant difference in initial valve thickness between the mixing strategies for 
valves used in the degradation study (Figure 21D). Representative valves from the soft segment 
mixed group, physically blended group, and co-stream electrospun group are shown in Figure 
22. Electrospun valves used in the degradation study demonstrated proper coaptation at rest after 
removal from the mandrel. 
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Figure 21. Characterization of the electrospinning deposition time vs. leaflet thickness for the mixing strategies A) 
soft segment mixing, B) physically blending, and C) co-stream electrospinning. D) Initial leaflet thickness of the 
degraded valves. 
 
 
Figure 22. Electrospun, biodegradable, fully assembled tissue engineered heart valves fabricated with each of the 
mixing strategies A) soft segment mixing, B) physical blending, and C) co-stream electrospinning. 
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3.3 TISSUE ENGINEERED HEART VALVE ACCELERATED IN VITRO 
DEGRADATION 
Scaffold polymer degradation was evaluated in a lipase solution at 37°C with mechanically 
loaded and unloaded environments. Videos of valve function in the pulse duplicator for all three 
experimental groups and at each timepoint can be found in the supplemental materials, with a 
brief description of the videos in Appendix A.1. Valve visual inspection, mass loss, and leaflet 
thickness loss were all used to evaluate the degradation. Lipase solution was changed twice per 
week to maintain consistent enzyme concentration and mitigate significant changes in pH [66]. 
3.3.1 Valve visual inspection  
Figure 23 shows the fully assembled valves following degradation in the pulse duplicator. 
Valves displayed little to no tearing at the commissures or annulus, but nearly all degraded 
valves had tearing in the belly region of the leaflet which extended up to the free edge in some 
cases. The spliced valve photos in Figure 24 further confirm this observation where some valves 
had tears down the middle of the leaflet which was fairly similar between the three leaflets. The 
co-spun valves displayed less tearing compared to the other two groups. Valve leaflets from the 
degradation experiment without mechanical loading had no tearing or hole formation, in any 
group, up to 14 days (Figure 25).  
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Figure 23. Visual inspection of the fully assembled valves following degradation in a mechanically demanding 
environment. 
 
 
Figure 24. Visual inspection of the spliced valves following degradation in a mechanically demanding environment. 
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Figure 25. Visual inspection of the leaflets following degradation without mechanical loading. 
 
3.3.2 Valve mass loss  
Results from the valve mass loss accelerated degradation study with lipase and a mechanically 
demanding environment are presented in Figure 26. Mass remaining was significantly less for 
the soft segment mixed group (78.2%) than the physically blended (87.8%) or co-spun (87.9%) 
groups at 14 days. Both soft segment mixed and physically blended valves showed gradual 
decreases in mass remaining, while the co-spun valves increased in mass remaining at 14 days 
compared to 7 days. 
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Figure 26. Valve mass remaining for electrospun tissue engineered heart valves fabricated with different mixing 
strategies and degraded in the pulse duplicator with mechanical loading and an enzymatic solution. 
 
Valve leaflets degraded without mechanical loading maintained a similar trend for mass 
remaining, with the soft segment mixed group degrading significantly faster than the co-spun 
group. All valve leaflets experienced a gradual loss of mass shown in Figure 27, with the mass 
remaining ranging from 91.8% to 94.2% for the three groups. In a degradation comparison 
between the mechanically loaded and unloaded valves, each mixing strategy showed faster 
degradation in a mechanically demanding environment at both 7 and 14 days (Figure 28).  
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Figure 27. Valve leaflet mass remaining for electrospun tissue engineered heart valves fabricated with different 
mixing strategies and degraded in an enzymatic solution without mechanical loading. 
 
 
Figure 28. Valve mass remaining degradation profiles of tissue engineered heart valves processed with A) soft 
segment mixing, B) physical blending, and C) co-stream electrospinning, with (loaded) and without (unloaded) a 
mechanically demanding environment. 
 
3.3.3 Leaflet thickness loss  
Polymer valve degradation was also evaluated from its effect on leaflet thickness. Interpolation 
of thickness remaining at fifteen points on the leaflet surface is shown in Figure 29. Most 
degraded valves showed a loss of thickness in the belly region and up to the free edge, consistent 
with the visual inspection. The soft segment mixed leaflets had lost significantly more thickness 
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at 14 days than the others. Co-spun leaflets had degradation that was more random throughout 
the study, consistent with mass loss and had lost the least thickness at 14 days. 
 
 
Figure 29. Degraded tissue engineered heart valve leaflet thickness remaining interpolation for fifteen points along 
the free edge, commissures, annulus, and in the belly region for valves degraded in the pulse duplicator with a 
mechanically demanding environment and enzymatic solution. 
 
The in vitro degradation of the leaflet thickness was also quantified and compared 
(Figure 30). Thickness loss maintained the same general order as the other degradation 
parameters, with soft segment mixed valves having experienced significantly more degradation 
than the co-spun valves, and thickness remaining ranging from 83.5% to 92.6%. Again, the co-
spun valves experienced more random degradation throughout the 14 days and increased in 
thickness remaining at 14 days compared to 3 days and 7 days. 
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Figure 30. Valve leaflet thickness remaining for electrospun tissue engineered heart valves fabricated through 
different mixing strategies and degraded in the pulse duplicator with a mechanically demanding environment and 
enzymatic solution. 
 
3.4 SURFACE MORPHOLOGY OF DEGRADED TISSUE ENGINEERED HEART 
VALVES 
Valve leaflet surface morphology was observed with a SEM for the mechanically loaded 
scaffolds. SEM images of the atrial and ventricular surfaces of the valve leaflets are shown in 
Figures 31-33 and Figure 34-36, respectively. Qualitative analysis confirms an initial fibrous 
scaffold on both surfaces for each experimental group. At low magnification, the soft segment 
mixed leaflet surface is noticeably broken apart with increasing prevalence at later timepoints. 
There is no major damage to the physically blended or co-spun leaflet surfaces up to 14 days. At 
a more moderate magnification where fibers appear, the soft segment mixed surface breaking 
apart becomes more apparent and the physically blended surface also appears to have a few areas 
which are broken. At high magnification, all groups maintained a fibrous structure and most 
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appeared to have fibers fraying, especially at the later timepoints. There was noticeably more 
damage on the soft segment mixed and physically blended surfaces at 14 days degradation. 
There were no major differences between the atrial and ventricular surfaces at any magnification.  
 
 
Figure 31. SEM images of the surface morphology of degraded leaflet atrial side at low magnification (25x). 
 
 68 
 
Figure 32. SEM images of the surface morphology of degraded leaflet atrial side at moderate magnification (250x). 
 
 
Figure 33. SEM images of the surface morphology of degraded leaflet atrial side at high magnification (1500x). 
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Figure 34. SEM images of the surface morphology of degraded leaflet ventricular side at low magnification (25x). 
 
 
Figure 35. SEM images of the surface morphology of degraded leaflet ventricular side at moderate magnification 
(250x). 
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Figure 36. SEM images of the surface morphology of degraded leaflet ventricular side at high magnification 
(1500x). 
 
3.5 BIAXIAL MECHANICAL RESPONSE OF DEGRADED TISSUE ENGINEERED 
HEART VALVES 
Degraded valves biaxial mechanical response was evaluated for the valve leaflets at each 
timepoint. Figure 37 shows the equi-stress biaxial response in the radial and circumferential 
directions over time. While there were no significant differences in compliance in any group 
throughout the degradation, the physically blended and co-spun groups trended toward increased 
compliance with longer degradation. The strain energy (Figure 38) was also calculated for each 
group over time without any significant results. In general, there was very little change in the soft 
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segment mixed group and slight increases in strain energy for the blended and co-spun groups. 
Leaflets were also evaluated under equi-tension testing, and the results in Figure 39 were similar 
to those of the equi-stress test. 
 
 
Figure 37. Equi-stress biaxial mechanical response of tissue engineered heart valve leaflets which were 
mechanically loaded and degraded in the pulse duplicator. 
 
 
Figure 38. Strain energy calculations from the equi-stress biaxial mechanical response in the previous figure for the 
degraded tissue engineered heart valve leaflets. 
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Figure 39. Equi-tension biaxial mechanical response of tissue engineered heart valve leaflets which were 
mechanically loaded and degraded in the pulse duplicator. 
 
3.6 POLYMER VISCOSITY OF DEGRADED TISSUE ENGINEERED HEART 
VALVES 
Inherent viscosity of the degraded polyurethane valves was calculated from the relative viscosity 
measured with an Ubbelohde viscometer and the solution concentration. Figure 40 shows the 
results of the normalized inherent viscosity of the degraded polyurethane valves with mechanical 
loading. Both the soft segment mixed (83.3%) and physically blended (90.6%) groups had 
significant decreases in viscosity as compared to the co-spun (98.3%) group at 14 days. 
Additionally, the co-spun group indicated nearly no loss in viscosity throughout the study while 
the soft segment mixed group had high variation at 3 days and 7 days. The inherent viscosity of 
the polyurethane valves can be found in Table 2.  
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Figure 40. Residual inherent polymer viscosity from the tissue engineered heart valves degraded in the pulse 
duplicator with mechanical loading and an enzymatic solution. 
 
Table 2. Degraded valve polymer inherent viscosity. 
 
0 Days 
(dL/g) 
3 Days 
(dL/g) 
7 Days 
(dL/g) 
14 Days 
(dL/g) 
Chemical 1.12 ± 0.02 1.12 ± 0.08 1.04 ± 0.11 0.94 ± 0.02 
Blended 1.30 ± 0.02 1.31 ± 0.02 1.23 ± 0.03 1.18 ± 0.03 
Co-spun 1.26 ± 0.04 1.26 ± 0.04 1.26 ± 0.03 1.24 ± 0.01 
 
3.7 BLOOD COMPATIBILITY OF TISSUE ENGINEERED HEART VALVES 
To evaluate platelet deposition onto the surface of the electrospun leaflets, a simple rocking test 
was performed with electrospun samples from each mixing strategy for 1.5 hours and platelets 
were quantified with a LDH assay, shown in Figure 41. Although the physically blended leaflets 
had a lower number of deposited platelets than the soft segment mixed and co-spun leaflets, the 
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results were not statistically significant. There was also high variability in the platelet 
quantification for the co-spun group compared to the other two groups. 
 
 
Figure 41. Platelet deposition quantified by a lactate dehydrogenase assay for the electrospun tissue engineered 
heart valves with the three mixing strategies. 
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4.0  DISCUSSION 
TEHVs offer the potential to overcome many of the drawbacks which exist with mechanical or 
bioprosthetic heart valves, namely chronic anticoagulation therapy and limited durability, and the 
related morbidity. The ability to degrade and regenerate living, functional tissue makes the 
pediatric population a target of this therapy. While biodegradable materials are typically used in 
the design of tissue engineered valves, specific degradation rates for those scaffolds are often 
unknown. In order to de-risk preclinical studies and provide controllable rates of scaffold 
degradation, furthers studies were needed to characterize the materials being used in the valve 
constructs. 
4.1 TISSUE ENGINEERED HEART VALVE DEGRADATION WITH 
POLYURETHANE SOFT SEGMENT MIXING STRATEGIES 
The rate at which a TEHV degrades in vivo is important to the formation of new functional 
tissue. Degradability of the scaffold should be tuned to match new tissue formation by ECM 
synthesis [92, 109]. Heart valve tissue is subjected to cyclic opening and closing more than 30 
million times each year, and the mechanical stresses of this motion can fatigue and degrade the 
valve. Continuous contact with blood and other factors can also influence the degradation rate, 
which also varies depending on other comorbidities. 
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Biodegradable polyurethanes have been established by incorporating segments with 
labile bonds into the polyurethane backbone [85]. Other studies have shown the ability to 
integrate polyether [86] or polycarbonate [64] along with polyester into the polyurethane to tune 
degradability. Electrospun scaffolds have been produced from the combination of multiple 
polymers that were mixed through soft segment mixing during synthesis to form a copolymer 
[76], physically blending in a common solvent [70], or co-stream electrospinning to produce a 
scaffold with two different fiber populations [73], although there has been no comparison 
between the three methods. 
The purpose of this study was to analyze the relative degradation rates of these three 
mixing strategies with a 50/50 ratio of polyester and polycarbonate soft segments in the 
polyurethane scaffolds. Of the two segments, polyesters have been shown to have a faster 
degradation rate than polycarbonates [64, 81, 99]. In this thesis, degradation rates were found to 
be significantly faster for the soft segment mixed valves (Figure 26) which had the more labile 
ester bonds integrated into every polymer chain and electrospun fiber. Unlike the other two 
groups which had polymer chains consisting of only polyester or only polycarbonate segments, 
theoretically each polymer chain in the soft segment mixed group contained polyester segments. 
Similar results were found with thickness loss (Figure 30) as the soft segment mixed group lost a 
greater amount of thickness during degradation. Entire polymer chains and fibers consisting of 
the slower degrading polycarbonate segments were present in the physically bended and co-spun 
groups, respectively, providing a level of structure during degradation that the soft segment 
mixed group did not have.  
Additional analysis of leaflet thickness using the interpolation maps (Figure 29) showed 
more degradation for the soft segment mixed group at 14 days, as well as significant degradation 
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in the belly region and up to the free edge for all groups. This corresponds to the images of the 
spliced valves (Figure 24) which display tears in the degraded valves extending from the belly 
region to the free edge. These tears typically began forming in the valves within a few hours of 
initiating the degradation study and were likely a result of valve contraction and enzymatic 
activity, further discussed in Appendix A.2 and A.3. The appearance of holes were not pieces of 
leaflet lost during the study, but rather tears that pulled apart due to the stresses on the leaflet. 
This shows the significance of fatigue testing [15, 33] prior to preclinical studies in order to de-
risk valve failure and harm to the animal.  
Previous studies with lipase enzyme and biodegradable polyurethanes [66, 99, 104, 105] 
showed rapid degradation with respect to the control in just a few days. This may account for the 
initial tearing of the valves at the thinnest locations on the leaflets. While the degradation of the 
three groups in this study was significantly slower than most of the groups in the previous 
studies, those studies mostly involved PEUU or a derivative. However, in the study by Ma et al. 
[99], a polyurethane with polycarbonate in the backbone showed little degradation in an lipase 
solution at 4 weeks. Hong et al. [64] reported no degradation of 50/50 PECUU scaffolds at 8 
weeks in vitro without an enzyme. Other factors such as solution volume, contact surfaces, and 
high pressures and fluid movement may have affected enzymatic degradation in the system. 
Co-spun TEHVs may have displayed more random degradation properties due to their 
fabrication process. Rather than an equal distribution of polyester and polycarbonate segments in 
the polymer chain or blended solution as the other two groups had, the co-spun group required 
equal deposition of the PEUU and PCUU fibers onto the mandrel during electrospinning. Unlike 
previous degradation studies [85, 87, 100] where multiple samples could be made simultaneously 
for a group, this study required each sample to be fabricated independently, increasing the 
 78 
variation of the samples. Because the two polymer streams were originating from opposite sides 
of the rotating mandrel, one polymer stream experienced an upward tangential velocity of the 
mandrel while the other stream experienced a downward tangential velocity, potentially affecting 
the electrodeposition process. These concerns will be further addressed in the limitations, Section 
5.2. 
Surface morphology from the SEM images showed significant degradation on the surface 
of the soft segment mixed valves (Figures 31, 34). These images at the surface level showed the 
valve breaking apart on both sides, atrial and ventricle, as degradation progressed. Physically 
blended and co-spun valves did not show significant fractures, all of which corresponds with the 
mass loss of the scaffold. At the fiber level (Figures 33, 36), fibers appear to be broken in both 
the soft segment mixed and physically blended groups. Additionally, the fractures from the low 
magnification image of the soft segment mixed valve surface can be clearly seen. 
Results from the inherent viscosity tests (Figure 39) generally agree with the results from 
the mass loss (Figure 26) as the degradation order of the three mixing strategies is maintained at 
14 days. Loss of molecular weight in the degraded polymer scaffolds is indicated by loss in 
inherent viscosity [64]. Therefore, significantly lower inherent viscosity for the soft segment 
mixed and physical blended scaffold indicate more chain scission. Theoretically, with perfect 
mixing, each of these groups had both polyester and polycarbonate groups in every electrospun 
fiber. Meanwhile, the co-spun scaffold had two different polyurethane fiber populations, one 
with polyester segments and one with polycarbonate segments, which could maintain the 
viscosity during degradation. All experiments in the degradation analysis had soft segment 
mixed valves degrading significantly faster than the co-spun valves, with blended valves 
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somewhere in between the two. Extending this study out to longer timepoints may provide more 
clarity on the relationship between the three mixing strategies. 
This is the first study to characterize and compare the relative degradation profile of the 
three mixing strategies: soft segment mixing, physical blending, and co-spinning, for two 
different polymers. Guan et al. [86] and Hong et al. [64] studied the ratio of labile segments 
incorporated into the polyurethane backbone, but did not consider other strategies to combine the 
segments. Previous studies have considered each of these three strategies independently [70, 73, 
76], but there has yet to be a comparative study. This work provides a way to tune degradability 
of polymers without having to alter the polymer chemistry. Additionally, alternative mixing 
strategies are presented as possibilities when working with two desirable polymers which could 
not be combined using a different method. 
4.2 EFFECTS OF MECHANICAL LOADING AND PULSATILE FLOW ON TISSUE 
ENGINEERED HEART VALVE DEGRADATION 
The in vivo degradation rates of polymers are typically faster than the in vitro degradation in a 
PBS solution. Enzymes such as lipase [66, 99, 104, 105, 107], elastase [90], and collagenase 
[101] have been added to in vitro studies to create accelerated degradation studies which more 
accurately represent the in vivo environment. Lipases have been used to a great effect, 
significantly degrading polyurethanes with polyester segments as compared to PBS alone. These 
studies consider hydrolytic and enzymatic degradation with the polymer scaffold, but often 
neglect the effects of mechanical degradation. 
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Cyclical opening and closing of the heart valves occurs more than 30 million times each 
year, causing the valves to experience high pressure and mechanical fatigue [15]. While some 
TEHV studies evaluate the degradation of the construct in vitro, mechanical degradation is 
usually ignored as flat sheets of polymer are degraded in solution [109, 111]. This study 
advances those shortcomings by introducing a pulse duplicator to simulate the effects of 
mechanical degradation in addition to subjecting the fully assembled TEHVs to hydrolytic and 
enzymatic degradation. To recapitulate the in vivo experience of an atrioventricular valve, 
sutures were used to connect the valve commissures with the posts to represent the chordae 
tendineae and papillary muscles in the heart. 
Comparing the images of the mechanically loaded and unloaded degraded valve leaflets 
(Figures 24, 25), significant differences in valve leaflet tearing is present at all timepoints, 
indicating that mechanical stresses played a role in leaflet tearing. At the 14 day timepoint in the 
unloaded leaflet, no tears had occurred in any group, yet all groups in the mechanically loaded 
valves formed holes or tears at 3 days. Two other experiments to analyze the causes of leaflet 
tearing are presented in Appendix A.2 and A.3. Contraction of the electrospun fibers followed by 
stretching in the pulse duplicator may have contributed to this effect. To prevent similar valve 
failure during the in vivo studies, valves should not be stretched to fit the annulus; rather, a 
broader range of mandrel diameters should be used to increase the available valve sizes. 
The relative degradation rates of the three mixing strategies maintained the same general 
order without mechanical loading as they did in the mechanically demanding environment 
(Figure 27). Co-spun valves degraded significantly less than the soft segment mixed valves, 
reinforcing the initial findings described in the previous section. With respect to each mixing 
strategy, the valves in the pulse duplicator had degraded significantly faster at the 7 and 14 day 
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timepoints than the leaflet without mechanical stimulation (Figure 28). This could be an effect 
of the mechanical stresses experienced by the valve as well as fluid flowing past at a higher 
velocity removing degraded polymer. Regardless, this emphasizes the importance of replicating 
the mechanical stresses that would normally be experienced by a TEHV construct in the heart 
during an in vitro degradation study. 
This is the first study to perform a degradation analysis on fully assembled TEHVs in a 
pulse duplicator which attempts to mimic the native conditions of the heart. Reimer et al. [33] 
performed a fatigue test in a pulse duplicator, but did not specifically evaluate scaffold 
degradation. Sant et al. [109] and Brugmans et al. [111] evaluated the degradation of heart valve 
leaflet material, but did not evaluate the material as an assembled scaffold in a pulse duplicator. 
In conclusion, this work demonstrates the need to create a mechanically demanding environment 
when performing degradation studies on dynamic tissues and provides a method for long term 
degradation studies with TEHVs.  
4.3 MECHANICAL STABILITY OF TISSUE ENGINEERED HEART VALVES 
FOLLOWING DEGRADATION 
The importance of mechanical properties in the design of TEHVs has been introduced in [15, 51, 
54]. Mechanical properties of TEHVs are generally evaluated through tensile testing, biaxial 
testing, flexural testing, and fatigue testing. From a mechanics approach, in-plane biaxial 
properties relate to proper valve coaptation and reduced regurgitation while out-of-plane flexure 
properties are important for the valve opening and closing millions of times per year [54]. 
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Additionally, these mechanical signals are important for cell migration, alignment, and 
differentiation on the scaffold, all of which are required for endogenous tissue growth. 
To accommodate these mechanical requirements in a biodegradable scaffold, proper 
stress transfer from the degrading valve to newly formed tissue is required. Success in this 
transfer is a function of the valve degradation rate matching the rate of newly synthesized ECM 
[92]. As the scaffold degrades, there should be a loss in mechanical strength leading to increased 
compliance of the scaffold material; in vivo, this would be augmented by new tissue providing 
increased mechanical strength over time. Consequences of early degradation are failure of the 
tissue at the site, which can be traumatic in heart valve applications, while late degradation can 
result in fibrosis and stiffening of the leaflets [64, 92]. Additionally, inappropriate mismatch in 
mechanical properties can hinder proper cell function.  
This study characterized the biaxial mechanical properties of the degraded valve from the 
pulse duplicator to determine the effect of degradation on mechanical compliance. The isotropic 
valves showed no significant changes in mechanical response during the 14 day degradation 
study (Figures 37, 39). However, the physically blended and co-spun valves appeared to have a 
slight increase in compliance as degradation progressed. The soft segment mixed valves had 
essentially no change in compliance at 14 days which is contrary to what would be predicted. 
Because this group had the most scaffold degradation, it would be expected that the mechanical 
strength would decrease and result in increased in-plane mechanical compliance. Additionally, 
the compliance in the radial and circumferential directions are similar throughout the degradation 
for all groups, indicating that the tissue maintains isotropy and that the direction of degraded 
fibers is random. Similar results were also observed in the strain energy calculation from the 
equi-stress biaxial test (Figure 38). Although the circumferential direction of the leaflet appears 
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to be gaining compliance in Figure 37 as degradation progresses, the strain energy analysis 
indicates that both directions have approximately the same strain energy and that the difference 
is an offset in the biaxial response. 
While some of these results are counterintuitive, an explanation may be that the slight 
changes in mechanics at 14 days degradation is simply noise and that longer degradation studies 
are needed before an accurate evaluation can be made. Regardless, each mixing strategy 
maintained the mechanical properties of the TEHV up to 14 days, indicating the possibility of 
using these polyurethanes in long studies without the risk of acute mechanical failure. 
4.4 BLOOD COMPATIBILITY WITH POLYURETHANE SOFT SEGMENT 
MIXING STRATEGIES 
TEHVs must have good blood compatibility throughout their temporary use as they will be in 
constant contact with blood. In fact, many in situ approaches to TEHVs, like that of Kluin et al. 
[50], rely on endogenous cells from the blood to populate the scaffold. Fortunately, the 
degradable, stentless design of this TEHV will require only short-term contact and will not leave 
foreign materials in the blood stream. If new tissue successfully forms around the TEHV, less 
polymer will be exposed to the blood as the valve continues to degrade. 
Gu et al. [107] showed a PCUU coating to have relatively less platelet deposition than 
PEUU, although the results were not significantly different. This study evaluated blood 
compatibility of TEHV leaflets consisting of equal amounts of polyester and polycarbonate soft 
segments in polyurethanes, but combined through the three mixing strategies described above. 
Quantitative platelet deposition (Figure 41) showed no significant difference between the 
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mixing strategies, indicating the position of the polyester and polycarbonate segments in the 
same polymer chain, in different polymer chains in the same electrospun fiber, and in different 
electrospun fibers did not affect blood compatibility. Considering this, selection of the mixing 
strategy to control degradation will not affect the blood compatibility of the valve. The high 
variability within the co-spun group is again reflective of the more significant sample to sample 
variation with this dual-stream electrospinning method. However, due to the small sample size 
and variation within the groups, further testing of the scaffolds produced in a more controlled 
manner should be performed to verify blood compatibility. 
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5.0  CONCLUSIONS 
TEHVs could one day offer a promising solution for those suffering from VHD in need of a 
replacement valve. As an alternative to the current clinical technologies (mechanical and 
bioprosthetic heart valves), TEHVs have the potential to regenerate functional, native tissue that 
overcomes many of the limitations of the current technology and reduces the need for future 
surgery. Electrospun heart valves are fibrous structures that have been shown to have 
controllable anatomical geometry, submicron fiber diameter, and mechanical properties [51]. 
These scaffolds are fully assembled, stentless, trileaflet valves made from biodegradable 
polyurethane elastomers without a cellular component. As an acellular scaffold, endogenous 
tissue growth would be required by cells populating the polymeric scaffold from either the 
circulating blood or the walls of the heart. It is desirable for scaffold degradation to evenly match 
new tissue growth, while maintaining sufficient mechanical strength to avoid tissue failure at the 
site. This thesis focused on the degradation effects that the three mixing strategies for 
polyurethanes with polyester and polycarbonate soft segments would have on TEHVs. Further 
assessment of ECM production and new tissue formation on the TEHV in vivo is needed before 
selecting the appropriate mixing strategy to match the degradation rate with new tissue 
formation.  
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5.1 SUMMARY OF CONCLUSIONS 
Three different mixing strategies of polyester and polycarbonate segments in a polyurethane 
were used to electrospin fully assembled, biodegradable TEHVs. An accelerated degradation 
study of these TEHVs performed in vitro in a pulse duplicator found that mixing both polyester 
and polycarbonate segments into the polyurethane backbone during synthesis had the fastest 
degradation rate. Meanwhile, the TEHVs produced from independent electrospun streams of 
PEUU and PCUU had the least amount of degradation at 14 days, although there was more 
variability within the group. TEHVs produced from electrospun blends of PEUU and PCUU in 
solvent were between the other two groups and significantly different depending on the 
experiment, giving it a moderate degradation rate. 
TEHVs were degraded in a pulse duplicator with the cyclical stresses of a valve opening 
and closing and sutures to replicate the chordae tendineae of the atrioventricular valves. These 
factors were intended to more accurately represent the native environment of a heart valve, and 
increased degradation rates of TEHVs from all mixing strategies were shown at 7 and 14 days. 
This result indicates that mechanical as well as enzymatic and hydrolytic degradation should be 
considered in degradation studies of dynamic tissue scaffolds like heart valves. 
 Biaxial mechanical properties of the TEHVs from each mixing strategy were maintained 
up to the 14 day timepoint. TEHVs produced through blending PEUU and PCUU into a solvent 
or electrospinning with two independent streams of PEUU and PCUU had a slight increase in 
compliance at the 14 day timepoint. Although this increase was not significant, it was contrary to 
what would be expected based on the scaffold degradation. These findings indicate that although 
the scaffolds have begun to degrade and lose mass, the mechanical properties are being 
maintained until new tissue could putatively support the stresses. 
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The mixing strategies of the polyurethane soft segments were not significantly different 
with regard to platelet deposition. Therefore, blood compatibility of the material will not need to 
be a selection factor for the appropriate polyurethane soft segment mixing strategy when 
attempting to match degradation rate with new tissue formation. 
5.2 STUDY LIMITATIONS 
One of the main limitations of this study is the sample to sample variability produced by the 
electrospinning process [125]. Variability can result from environmental factors such as humidity 
and temperature, and although the temperature during the fabrications remained constant at 
~21°C, humidity would vary between 9% to 45%. Small differences in polymer concentration or 
variable loss in continuity of the mandrel and electrode could also alter the fabrications. Unlike 
previous degradation studies [85, 87, 104] which could generate all of the samples from a group 
in one fabrication, each sample had to be fabricated independently in this study, amplifying the 
effects described above. These repeatability issues of electrospinning are acknowledged as a 
concern for using this method to produce TEHVs. 
The design of the mandrel was another limitation in the study. Although the mandrel 
consisted of a conductive and a non-conductive component, fibers would not always deposit on 
the collecting surface, but would form a bridge between the commissures of the mandrel. 
Utilizing a material like copper as the conductive component may increase deposition onto the 
concave surface. Additionally, the high rotational speeds required for anisotropy [51, 67] could 
not be achieved as fibers had more difficulty depositing on the surface with high tangential 
velocity; therefore, rotational speed was modified to produce isotropic leaflets. 
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Another limitation to this study was the small sample size (n = 3/group/timepoint) and 
the fairly short degradation timepoints. Although longer timepoints [66, 104, 105] would have 
been beneficial to understanding the long-term performance of the valves, previous studies [66, 
99, 104, 105] using lipase with the biodegradable polyurethanes were performed for only a few 
weeks with significant degradation. Two weeks was selected as the final timepoint based on 
these previous enzymatic studies along with the study by Reimer et al. [33] which fatigue tested 
valves for 2 weeks. Experimentally, testing a single valve at a time in the pulse duplicator limited 
the number and length of experiments. This, along with the amount of material required for each 
scaffold, prevented the testing of fast degrading PEUU valves and slow degrading PCUU valves 
as controls. 
Due to the number of fabrications and required polymer for each valve, several different 
batches of each polyurethane had to be synthesized to complete this study. Therefore, polymer 
batch to batch variability may have also contributed to the experimental variation. Although the 
viscosity was evaluated for each batch, and the results for each polyurethane type (PEUU, 
PECUU, PCUU) were relatively similar to, but slightly higher than, previously reported 
literature values [64], changes in solution viscosity can vary the electrospinning process and fiber 
diameter of the scaffold [65]. 
Characterization methods such as proton nuclear magnetic resonance (1H NMR), Fourier 
transform infrared (FTIR) spectroscopy, differential scanning calorimetry (DSC), and size-
exclusion chromatography are other methods that have been used to characterize the series of 
degradable polyurethanes (PEUU, PECUU, PCUU) [64, 85, 86]. Because the synthesis has been 
extensively repeated and characterized, and in the interest of conserving resources, these 
experiments were not included in this study. However, the lack of these experiments potentially 
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limit the study in that the molecular weight, presence of monomers, or functional groups are not 
identified after synthesis or throughout the degradation study. 
A more philosophical limitation to this study is the ability to accurately replicate the in 
vivo environment experienced by heart valves. Solution contents and viscosity in the pulse 
duplicator varied from the blood in the circulatory system. Viscosity is higher for blood than the 
PBS solution and can be represented with a 40% glycerol solution as used in [51]. The proteins 
(enzymes) and cells (macrophages) in the circulatory system likely cause different degradation 
rates with the TEHVs than the lipase enzyme typically found in the pancreas. Additionally, the 
valve positioning apparatus and holder did not replicate the hemodynamics of the native heart, 
and the pressures from the PVAD exceeded those experienced in the human body. 
5.3 FUTURE DIRECTIONS 
The results from the degradation study presented in the previous sections add to the scientific 
knowledge of designed degradability of polyurethanes and specifically to biodegradable TEHVs. 
This work contributes to the development of a novel TEHV that supports endogenous tissue 
growth by degrading at a controlled rate which can be tuned to match new tissue formation. The 
following are ongoing research opportunities outside of the objectives of this thesis that both 
inspired and may benefit from this study and the results herein. 
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5.3.1 Development of a novel tissue engineered heart valve 
Inspiration for this study stemmed from the concept of a novel method for producing TEHVs 
presented by D’Amore et al. [51]. As previously mentioned, the concept of double component 
deposition was introduced with a complex, anatomically inspired mandrel to produce electrospun 
heart valves. The two-component mandrel used conductive and non-conductive materials to 
direct electrospun fiber deposition onto the surface of a complex geometry. As a result, a fully 
assembled, stentless, trileaflet heart valve with microscopic fibers could be produced. 
The acellular scaffold was fabricated with a biodegradable polyurethane with the 
intention of being a temporary mechanical support while providing a matrix with aligned fibers 
for new tissue growth. Lacking a cellular component, this construct was intended to rely on 
endogenous tissue growth by recruiting local and circulating cells to populate the scaffold. The 
study employed PEUU, a stronger yet fast degrading polyurethane, as mentioned in Section 
1.4.3, to prevent mechanical failure. 
This study further characterized important mechanical properties defined by [54] as well 
as macro- and micro-structure of native porcine heart valves and implemented these same 
properties into the novel TEHV. In-plane biaxial mechanical properties were tuned to match the 
native valve anisotropy by modifying the rotational speed of the mandrel [67] while out-of-plane 
flexural properties were matched by altering the translational speed [68]. Native leaflet thickness 
was matched by controlling the deposition time of polymer onto the mandrel, while fiber 
diameter was defined by voltage difference, polymer concentration, and gap distance, also 
defined in [65]. Functionally, the performance of the engineered valve in situ and in vitro was 
similar to that of a native porcine tricuspid valve coaptation and a state-of-the-art bioprosthetic in 
a pulse duplicator, respectively. Finally, the ability to apply the DCD technique to each heart 
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valve geometry was exemplified through the production of a TEHV with the various geometries 
and sizes. 
The results from the degradation study in the previous sections have the ability to 
augment this study by D’Amore et al. [51] by providing a method for tuning the degradation 
rates of the construct to match the rate of endogenous tissue growth. While it is recognized that 
this study was limited to 2 weeks and performed in vitro, it provides a starting point for tweaking 
the degradation rate of the engineered valves. Similar to how mechanics and structure were 
controlled through the fabrication process [51], this study indicates a way for controlling the 
degradation in a similar approach.  
5.3.2 Ongoing in vivo studies with the tissue engineered heart valves 
There are several current ongoing in vivo studies evaluating the TEHVs introduced by D’Amore 
et al. [51]. Current studies use an acute porcine model (≤ 24 hours) to understand the valve 
functionality and surgical approach to the different engineered heart valves. To date, there have 
been four approaches attempted with this electrospun valve construct: pulmonary valve with a 
magnesium stent (n = 5), stentless tricuspid valve (n = 8), mitral valve with a nitinol stent (n = 
1), and stentless mitral valve (n = 4). Surgical methods for performing the valve replacement 
with each engineered construct have been improved to minimize cardiopulmonary bypass time. 
Stented pulmonary valves and stentless tricuspid valves have been successful in the acute in vivo 
setting with three animals surviving up to 24 hours. Additionally, the valves showed no to mild 
regurgitation from epicardial echocardiography, and leaflets displayed no thrombus formation, 
no mechanical failure, and no degradation. Mitral valve replacements were not as successful, due 
in large part to a small, stiff anterior leaflet which lacked sufficient function. 
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Valve leaflets for the acute in vivo studies were fabricated from PCUU, a mechanically 
weaker, but less thrombogenic polyurethane. This slower degrading polyurethane was sufficient 
for an acute study where tissue growth was not expected, but longer chronic studies will require 
appropriate degradation rates to account for new tissue growth. Hashizume et al. [82] concluded 
that PECUU (i.e. the soft segment mixed group in this thesis) produced the optimal outcome in a 
cardiac patch study. Success in the acute valve studies indicates the potential for chronic animal 
studies to characterize the construct performance over several months as well as endogenous 
tissue growth, scaffold degradation, and mechanical response. As described in Section 5.3.1, this 
degradation study provides another method for tuning the degradation rates of TEHVs to be used 
in chronic in vivo studies by altering fabrication conditions. 
5.3.3 Long term degradation analysis in the pulse duplicator 
The degradation study described in this thesis focused on a symmetrical, trileaflet heart valve in 
a pulse duplicator. As listed in Section 5.3.2, TEHVs with different geometries, sizes, and two or 
three leaflets will be used in chronic studies. Performance and fatigue of these different valves 
should be evaluated in vitro before performing the chronic studies, and the pulsatile flow system 
used in this degradation study provides a way to evaluate these constructs. 
This study provides the groundwork for degradation testing in vitro. Section 3.3.2 
indicates the effect of performing degradation analysis in a mechanically demanding 
environment. The pulse duplicator described in this thesis provides a system with constant 
pulsatile flow, physiologically relevant temperature, and enzymatic solution to more accurately 
represent the in vivo environment. Additionally, the valve positioning apparatus shown in 
Section 2.4 contains three metallic posts to which the commissures of the valve are connected by 
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two loops of suture. These represent the chordae tendineae of the native heart valve which 
connect the atrioventricular valves with the papillary muscles in the ventricles. This is an 
important feature when considering the stresses, and consequent degradation, applied to the 
engineered valves. Figure 42 shows two additional valve positioning apparatuses which have 
been designed according to the size and geometry of the valves for the in vivo studies. These are 
intended to evaluate the performance, fatigue, and degradability of the TEHVs before chronic 
studies by studying the valves in the pulse duplicator for several months. 
 
 
Figure 42. New valve positioning apparatuses for A) mitral valve geometries and B) tricuspid valve geometries with 
a larger anterior leaflet. 
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APPENDIX A 
ADDITIONAL VALVE DEGRADATION VIDEOS AND STUDIES 
Descriptions of the videos of valve function in the pulse duplicator as well as two additional 
experiments to assess the rapid leaflet tearing and hole formation are included in this appendix. 
A.1 REPRESENTATIVE VALVE FABRICATION, PULSE DUPLICATOR, AND 
DEGRADATION VIDEOS 
Representative videos for the TEHV electrospinning process, pulse duplicator side and front 
views, and degraded valve function in the pulsatile duplicator are available in the supplemental 
material. Brief, accompanying descriptions of the videos are provided in this section. 
 
Video 1: Representative video showing the electrospinning process to fabricate fully assembled, 
trileaflet, biodegradable heart valves using the heart valve-shaped mandrel. 
Video 2: Representative video of an electrospun TEHV in the pulse duplicator; front view 
showing the leaflet coaptation at the free edge during pulsatile flow. 
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Video 3: Representative video of an electrospun TEHV in the pulse duplicator; side view 
showing the sutures from the commissures to the posts to simulate chordae tendineae. 
Video 4: Soft segment mixed electrospun TEHV at 0 days of degradation. 
Video 5: Soft segment mixed electrospun TEHV at 3 days of degradation. 
Video 6: Soft segment mixed electrospun TEHV at 7 days of degradation. 
Video 7: Soft segment mixed electrospun TEHV at 14 days of degradation. 
Video 8: Physically blended electrospun TEHV at 0 days of degradation. 
Video 9: Physically blended electrospun TEHV at 3 days of degradation. 
Video 10: Physically blended electrospun TEHV at 7 days of degradation. 
Video 11: Physically blended electrospun TEHV at 14 days of degradation. 
Video 12: Co-stream electrospun TEHV at 0 days of degradation. 
Video 13: Co-stream electrospun TEHV at 3 days of degradation. 
Video 14: Co-stream electrospun TEHV at 7 days of degradation. 
Video 15: Co-stream electrospun TEHV at 14 days of degradation. 
A.2 ANALYSIS OF LEAFLET TEARS AND HOLE FORMATION 
Within a few hours from the start of the degradation study, holes would begin forming in the 
belly region of the leaflets. A brief experiment was conducted to gain some insight into this 
phenomenon and to understand if certain factors (e.g. buffer solution, solution temperature, 
enzyme, degradability of polymer) or combinations of factors were causing this effect. Six 
conditions were tested: 1) deionized water, room temperature, and a PEUU TEHV, 2) deionized 
water, physiological temperature, and a PEUU TEHV, 3) tap water, physiological temperature, 
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and a PEUU TEHV, 4) PBS, physiological temperature, and a PEUU TEHV, 5) PBS, lipase, 
physiological temperature, and a PEUU TEHV, and 6) PBS, lipase, physiological temperature, 
and a nondegradable Tecoflex™ polyurethane (Lubrizol, Wickliffe, OH) TEHV. PEUU was 
selected as the degradable polymer since it has the fastest degradation rate. TEHVs were tested 
for 3 hours in the pulse duplicator under the conditions listed above. Videos of valve function for 
the six conditions can be found in the supplemental materials and a description of each is 
provided below. Figure 43 shows the six valves, and only the PEUU valve with lipase had tears 
and holes in the leaflets at 3 hours. While the tearing may result from the interplay of several 
factors, the enzyme appears to have a significant role in initiating this effect. 
 
 
Figure 43. Visual inspection of spliced valves after 3 hours of degradation with A) degradable polyurethane in 
deionized water at 23°C, B) degradable polyurethane in deionized water at 37°C, C) degradable polyurethane in tap 
water at 37°C, D) degradable polyurethane in PBS at 37°C, E) degradable polyurethane in PBS + lipase at 37°C, and 
F) nondegradable polyurethane in PBS + lipase at 37°C. 
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Video 16: PEUU TEHV in deionized water at 23°C at 3 hours. 
Video 17: PEUU TEHV in deionized water at 37°C at 3 hours. 
Video 18: PEUU TEHV in tap water at 37°C at 3 hours. 
Video 19: PEUU TEHV in PBS at 37°C at 3 hours. 
Video 20: PEUU TEHV in PBS with lipase at 37°C at 3 hours. 
Video 21: Nondegradable polyurethane TEHV in PBS with lipase at 37°C at 3 hours. 
A.3 ANALYSIS OF VALVE CONTRACTION FOLLOWING FABRICATION 
Contraction of the valve construct [126] may have been another factor in the formation of holes 
and tearing in the leaflet. During fabrication of valves for the in vivo studies described in Section 
5.3.2, it was noted that the diameter of the annulus is smaller than the mandrel dimensions. The 
mandrel used in this thesis had a diameter of 40 mm, and the valve positioning apparatus 
contained a 40 mm ring which the valve had to be stretched over when loading it into the system. 
Valve contraction by just a few millimeters in diameter may have put an unnecessary stress 
concentration on the valve scaffold, which may have assisted in the hole formation at the thinnest 
locations: the belly region and free edge of the leaflets. Table 3 below lists the mixing strategies 
and the true valve scaffold diameter for the symmetrical 40 mm tricuspid mandrel, while Table 4 
compares the valve mandrel diameters used for the in vivo studies to the true valve diameter 
using PCUU. To compensate for the contraction and provide the correct annulus dimensions, the 
valve positioning apparatuses shown in Section 5.3.3 Figure 42 were scaled to match the true 
valve diameter.  
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Table 3. Electrospun valve diameter and contraction following fabrication for the three mixing strategies. 
Mixing Strategy 
Mandrel Diameter 
(mm) 
Valve Diameter 
(mm) 
Contraction 
(%) 
Chemical 40.0 37.3 ± 0.2 6.7 ± 0.5 
Blended 40.0 37.9 ± 0.4 5.1 ± 1.1 
Co-spun 40.0 37.4 ± 0.3 6.5 ± 0.8 
 
 
Table 4. Electrospun valve diameter and contraction following fabrication with the new mandrels for in vivo studies. 
Mandrel Geometry 
Mandrel Diameter 
(mm) 
Valve Diameter 
(mm) 
Contraction 
(%) 
Tricuspid 26.0 24.0 ± 0.3 7.7 ± 1.1 
Tricuspid 30.0 26.9 ± 0.2 10.3 ± 0.6 
Tricuspid 34.0 31.1 ± 0.6 8.6 ± 1.7 
Mitral 24.0 22.4 ± 0.2 6.8 ± 1.7 
Mitral 30.0 26.8 ± 0.2 10.7 ± 0.7 
Mitral 34.0 31.0 ± 0.7 8.9 ± 0.2 
Aortic/Pulmonary 20.0 18.5 ± 0.4 7.5 ± 1.9 
Aortic/Pulmonary 23.0 21.6 ± 0.2 6.2 ± 0.7 
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